<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">As filed with the Securities and Exchange
Commission on May 29, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration Statement No. 333-</B>[______]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Under</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>THE SECURITIES ACT OF 1933</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: ?; font-size: 14pt"><B>SELLAS
Life Sciences Group, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 33%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Delaware</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or other jurisdiction of</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>incorporation or organization)</B></P></TD>
    <TD STYLE="vertical-align: bottom; width: 34%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2834</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Primary Standard Industrial</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Classification Code Number)</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>15 West 38<SUP>th </SUP>St., 10<SUP>th</SUP>
        Floor</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, NY 10018</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(917) 438-4353</B></P></TD>
    <TD STYLE="vertical-align: top; width: 33%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>20-8099512</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(I.R.S. Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification Number)</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-bottom: 6pt; font-size: 10pt; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>(Address, including zip code, and telephone number, including area code, of registrant&rsquo;s principal executive offices)</B></FONT></P>
                                                                                <P STYLE="border-bottom: Black 1pt solid; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Angelos M. Stergiou, M.D., Sc.D., h.c.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>President and Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SELLAS Life Sciences Group, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>15 West 38<SUP>th </SUP>St., 10<SUP>th</SUP>
Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, NY 10018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(917) 438-4353</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name, address, including zip code, and
telephone number, including area code, of agent for service)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Copies to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Joel I. Papernik</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Daniel A. Bagliebter</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Mintz, Levin, Ferris, Cohn, Glovsky &amp;
        Popeo, P.C.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>666 Third Avenue</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, NY 10017</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tel: (212) 935-3000</B></P></TD>
    <TD STYLE="vertical-align: bottom; width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Barbara Wood</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Executive Vice President, General</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Counsel &amp; Secretary</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SELLAS Life Sciences Group, Inc.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>15 West 38<SUP>th</SUP> St.,
10<SUP>th</SUP> Floor</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, NY 10018</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tel: (917) 438-4353</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Approximate date of commencement of proposed sale to public:
</B>As soon as practicable after this Registration Statement is declared effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If any of the securities being registered on this Form are to
be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is filed to register additional securities for
an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is a post-effective amendment filed pursuant to
Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or emerging growth company. See the definitions
of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo; and &ldquo;emerging
growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: left"><FONT STYLE="font-size: 10pt">Large accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 57%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: left"><FONT STYLE="font-size: 10pt">Accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: right"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#120;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#120;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Emerging growth company</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CALCULATION OF REGISTRATION FEE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Title of Each Class of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Securities to be Registered</B></P></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount to be Registered (1)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Proposed<BR>
 Maximum<BR>
 Offering<BR>
 Price per<BR>
 Share</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proposed<BR>
 Maximum</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aggregate</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offering Price</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registration Fee (2)</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: left">Common Stock, $0.0001 par value per share, underlying the investor warrants</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">818,900</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">3.93</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">3,218,277</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">417.73</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>All of the shares of common stock offered hereby are for the account of selling stockholders and consist of 818,900 shares
issuable upon the exercise of warrants (the &ldquo;Warrants&rdquo;). Pursuant to Rule 416 of the Securities Act of 1933, as amended
(the &ldquo;Securities Act&rdquo;), this registration statement also covers any additional shares of common stock which become
issuable by reason of any share dividend, share split, recapitalization or any other similar transaction without receipt of consideration
which results in an increase in the number of shares of common stock outstanding.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act based
upon the higher of (i) the price at which the warrants may be exercised, and (ii) $3.67, the average of the high and low prices
for a share of the registrant&rsquo;s common stock as reported on The Nasdaq Capital Market on May 27, 2020, which date is a date
within five business days of the filing of this registration statement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The registrant hereby amends this Registration Statement
on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Commission, acting pursuant
to said Section 8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #EB0029"><B>The information contained in this preliminary
prospectus is not complete and may be changed. The selling stockholders identified in this prospectus may not sell these securities
until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is
not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer
or sale is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #EB0029">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #EB0029"><B>SUBJECT TO COMPLETION,
DATED MAY 29, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #EB0029">&nbsp;</P>



<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #EB0028"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #EB0028"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2021170-1_s1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>818,900 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus relates to the resale of
up to 818,900 shares of our common stock issuable upon exercise of certain outstanding warrants issued by us in a private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are not selling any shares of common
stock and will not receive any proceeds from the sale of the warrant shares by the selling stockholders under this prospectus.
Upon the exercise of the warrants for all 818,900 shares of our common stock by payment of cash, however, we will receive aggregate
gross proceeds of approximately $3.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">These shares will be resold from time to
time by the entities listed in the section titled &ldquo;Selling Stockholders&rdquo; beginning on page 6, which we refer to
as the selling stockholders. The shares of common stock offered under this prospectus by the selling stockholders are issuable
upon exercise of warrants issued in a private placement pursuant to the Securities Purchase Agreement entered into by and among
SELLAS Life Sciences Group, Inc. and the selling stockholders, dated as of January 9, 2020 (the &ldquo;Purchase Agreement&rdquo;).
We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of securities by
the selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The selling stockholders may sell the shares
of common stock described in this prospectus in a number of different ways and at varying prices. We provide more information about
how a selling stockholder may sell its shares of common stock in the section titled &ldquo;Plan of Distribution&rdquo; on page
8. We will pay the expenses incurred in registering the securities covered by the prospectus, including legal and accounting
fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our common stock is traded on The Nasdaq
Capital Market under the symbol &ldquo;SLS&rdquo;. On May 27, 2020, the last reported sale price of our common stock was $3.60
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in our common stock involves a high degree of risk.
See &ldquo;Risk Factors&rdquo; beginning on page 5 of this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission, or the SEC,
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is May [___],
2020.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; padding-bottom: 3pt"><A HREF="#a_001">PROSPECTUS SUMMARY</A></TD>
    <TD STYLE="width: 10%; text-align: right; padding-bottom: 3pt"><A HREF="#a_001">1</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 3pt"><A HREF="#a_002">THE OFFERING</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 3pt"><A HREF="#a_002">4</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 3pt"><A HREF="#a_003">RISK FACTORS</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 3pt"><A HREF="#a_003">5</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 3pt"><A HREF="#a_004">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 3pt"><A HREF="#a_004">5</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 3pt"><A HREF="#a_005">USE OF PROCEEDS</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 3pt"><A HREF="#a_005">6</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 3pt"><A HREF="#a_006">SELLING STOCKHOLDERS</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 3pt"><A HREF="#a_006">6</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 3pt"><A HREF="#a_007">PLAN OF DISTRIBUTION</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 3pt"><A HREF="#a_007">8</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 3pt"><A HREF="#a_008">DESCRIPTION OF CAPITAL STOCK</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 3pt"><A HREF="#a_008">10</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 3pt"><A HREF="#a_009">LEGAL MATTERS</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 3pt"><A HREF="#a_009">14</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 3pt"><A HREF="#a_010">EXPERTS</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 3pt"><A HREF="#a_010">14</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 3pt"><A HREF="#a_011">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 3pt"><A HREF="#a_011">14</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 3pt"><A HREF="#a_012">INCORPORATION OF DOCUMENTS BY REFERENCE</A></TD>
    <TD STYLE="text-align: right; padding-bottom: 3pt"><A HREF="#a_012">14</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should rely only on the information we have included or
incorporated by reference into this prospectus. We have not authorized anyone to provide you with any representation other than
those contained or incorporated by reference into this prospectus. You must not rely upon any information or representation not
contained or incorporated by reference into this prospectus. This prospectus does not constitute an offer to sell or the solicitation
of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such
jurisdiction. You should not assume the information contained in this prospectus is accurate on any date subsequent to the date
set forth on the front of the document or that any information we have incorporated by reference herein is correct on any date
subsequent to the date of the document incorporated by reference, even though this prospectus is delivered, or securities are sold,
on a later date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;SELLAS Life Sciences Group, Inc.,&rdquo; &ldquo;SELLAS,&rdquo;
the SELLAS logo, and other trademarks or service marks of SELLAS appearing in this prospectus are the property of our company.
Other third-party logos and product/trade names are registered trademarks or trade names of their respective companies. Solely
for convenience, trademarks and tradenames referred to in this prospectus appear (after the first usage) without the &reg; and
 &trade; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent
under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus contains or incorporates by reference summaries
of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete
information. All the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred
to herein have been filed or have been incorporated by reference as exhibits to the registration statement of which this prospectus
forms a part, and you may obtain copies of those documents as described in this prospectus under the heading &ldquo;<I>Where You
Can Find More Information</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Smaller Reporting Company &ndash; Scaled
Disclosure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to Item 10(f) of Regulation S-K promulgated under the
Securities Act of 1933, as indicated herein, we have elected to comply with the scaled disclosure requirements applicable to &ldquo;smaller
reporting companies,&rdquo; including providing two years of audited financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<!-- Field: Split-Segment; Name: 2 -->
<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This summary highlights information contained in other parts
of this prospectus. Because it is only a summary, it does not contain all the information you should consider before investing
in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information
appearing elsewhere in this prospectus and the information incorporated by reference herein. You should read all such documents
carefully, especially the risk factors and our audited consolidated financial statements and the related notes included herein,
before deciding to buy our securities. Unless the context requires otherwise, references in this prospectus to &ldquo;SELLAS,&rdquo;
 &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to SELLAS Life Sciences Group, Inc. and our
subsidiaries.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a late-stage clinical biopharmaceutical company focused
on developing novel cancer immunotherapeutics for a broad range of cancer indications. Our product candidates currently include
galinpepimut-S and nelipepimut-S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Galinpepimut-S, or GPS</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our lead product candidate, galinpepimut-S, or GPS, is a cancer
immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein,
which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has potential
as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers
and solid tumor indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2020, we commenced a Phase 3 trial for GPS monotherapy
in patients with acute myeloid leukemia, or AML, in the maintenance setting after achievement of their second complete remission,
or CRem2, following successful completion of second-line antileukemic therapy, which we refer to as the REGAL study. We expect
this study will be used as the basis for a Biologics License Application, or BLA, submission, subject to a statistically significant
and clinically meaningful data outcome and agreement with the U.S. Food &amp; Drug Administration, or the FDA. The study is expected
to enroll approximately 116 patients at approximately 50 clinical sites in the United States and Europe and is contemplated to
have a planned interim safety and futility analysis after 80 events (deaths).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2018, we initiated a Phase 1/2 multi-arm (&ldquo;basket&rdquo;
type) clinical study of GPS in combination with Merck &amp; Co., Inc.&rsquo;s anti-PD-1 therapy, Keytruda&reg; (pembrolizumab).
We plan to enroll up to approximately 90 patients at up to 20 centers in the United States. The initial tumor types being studied
are ovarian cancer (second or third line) and colorectal cancer (third or fourth line) with up to approximately 40 patients in
total in these two indications, to be followed by AML (in patients having achieved partial response as their best hematological
response after four cycles of therapy with hypomethylating agents), triple negative breast cancer, or TNBC, (second line), and
small cell lung cancer, or SCLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">GPS was granted Orphan Drug Product Designations from the FDA,
as well as Orphan Medicinal Product Designations from the European Medicines Agency, or EMA, for GPS in AML, malignant pleural
mesothelioma, or MPM, and multiple myeloma, or MM, as well as Fast Track Designation for AML, MPM, and MM from the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Nelipepimut-S or NPS</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nelipepimut-S, or NPS, is a cancer immunotherapy targeting the
human epidermal growth factor receptor 2, or HER2, expressing cancers. Data presented in 2018 from a Phase 2b clinical trial of
the combination of trastuzumab (Herceptin&reg;) plus NPS in HER2 low expressing (1+ or 2+ per immunohistochemistry, or IHC) breast
cancer patients in the adjuvant setting to prevent recurrences showed a clinically and statistically significant improvement in
the disease-free survival, or DFS, rate for the TNBC cohort at 24 months for patients treated with NPS plus trastuzumab of 92.6%
compared to 70.2% for those treated with trastuzumab alone. Following ongoing discussions with the FDA and based upon written feedback
from the FDA and on the totality of clinical, safety and translational NPS data to date, we have finalized the design and plan
for a Phase 3 registration-enabling study of NPS in combination with trastuzumab for the treatment of patients with TNBC in the
adjuvant setting after standard treatment. If successful, we believe this study may be considered as the basis for a BLA submission
to the FDA. We are seeking out-licensing opportunities to fund and conduct the future clinical development of NPS in order to maximize
the potential of the program and we do not plan to conduct and fund a Phase 3 program for NPS on our own.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>FBP-targeting bivalent vaccine (GALE-301/-302)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to prioritize development of our core assets, we have
determined to cease development of GALE-301 and GALE-302, cancer immunotherapies that target the E39 peptide derived from the folate
binding protein, or FBP, which were licensed in from The Henry M. Jackson Foundation, or HJF, and the MD Anderson Cancer Center,
or MDACC. We are currently negotiating a termination of the license agreement with HJF and MDACC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The chart below summarizes the current status of our clinical
development pipeline:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2021170-1_s1img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cancer Immunotherapy Market Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">According to a January 2020 report by Kelly Scientific Publications,
cancer immunotherapy drugs have already captured nearly 50% of the overall oncology drugs market in 2019, generating about $75
billion in that year alone, and are forecast to surpass $115 billion in 2023. Additionally, an October 2019 Allied Market Research
report on the estimated entire market value of oncology drugs (of any type) suggests that cancer immunotherapies could represent
up to 77% of that total value by 2023. According to a report published in September 2018, it was projected that approximately 70%
of the 2019 immunotherapy market would be comprised of checkpoint inhibitors (~30% of the market share), immune synapse co-stimulators
and bispecific monoclonal antibodies (~40% of the market share), as well as approximately 30% of other immunotherapies, including
chimeric antigen receptor (CAR) T-cell therapies and other cell-based modalities (e.g., ex vivo modified natural killer or NK cells).
It is predicted that the checkpoint inhibitor market share will decrease slightly by 2023, reaching a 27% value (from a 30% value
in 2019), as novel therapies, including peptide cancer active immunizers (vaccines) such as our product candidates, GPS and NPS
and cell-based therapies, advance into regulatory approvals and use in the cancer market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The total number of newly diagnosed patients with AML per year
in the United States is approximately 21,450 (2019 epidemiological data: American Cancer Society). It is estimated that the number
of adult patients of any age with AML in the United States per year who successfully enter into CRem2, the indication of our REGAL
study, is approximately 2,000 patients and approximately 4,700 patients outside of the United States in the rest of the world,
or ROW, while the number of patients who achieve CRem1 is estimated to be approximately 16,400 patients in the United States and
approximately 38,100 patients ROW. The number of patients potentially eligible for GPS maintenance therapy after achievement of
CRem2 status is approximately 1,200 patients in the United States and approximately 2,800 patients ROW.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 11, 2020, the World Health Organization declared the
outbreak of a new coronavirus to be a &ldquo;pandemic.&rdquo; First identified in 2019 and known now as COVID-19, the outbreak
has resulted in various &ldquo;stay-at-home&rdquo; and &ldquo;shutdown&rdquo; orders through the various states in the United States
as well as most countries worldwide. The pandemic has impacted millions of individuals and businesses worldwide. As we have functioned
operationally as a semi-virtual company, the transition to &ldquo;work-from home&rdquo; for our employees has not materially altered
our business operations. Our Phase 3 REGAL study is in its early stages, with the necessary work to activate additional sites in
the United States and Europe continuing without material interruption. Screening is ongoing at the majority of the sites in the
GPS + pembrolizumab combination study although certain sites have limited operations to some extent. Due to the uncertainty of
these limitations regarding the sites, we now expect initial clinical data in the first half of 2021. We have been informed by
MSK that while it is continuing to dose the patients already enrolled in the MPM IST, it is not currently enrolling additional
patients. We believe that the COVID-19 pandemic has not materially impacted our efforts to out-license NPS. The extent to which
the coronavirus impacts the Company's operations will depend on future developments, which are highly uncertain and cannot be predicted
with confidence, including the duration of the outbreak, the re-emergence of a second outbreak in the fall or winter, new information
which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among
others. In particular, the continued spread of the coronavirus globally could adversely impact the Company's clinical trial operations
and could have an adverse impact on the Company's business and the Company's financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Associated with Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our business is subject to a number of risks of which you should
be aware before making an investment decision. These risks are discussed more fully in the &ldquo;<I>Risk Factors</I>&rdquo; section
of this prospectus immediately following this prospectus summary. These risks include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our business may be adversely affected by the recent coronavirus outbreak.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing
losses for the foreseeable future.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will need significant additional financing to fund our operations and complete the development and, if approved, the commercialization
of our product candidates. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our
product development programs or commercialization efforts.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We currently have no source of revenues. We may never generate revenues or achieve profitability.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We expect to continue to incur significant operating and non-operating expenses, which may make it difficult for us to secure
sufficient financing and may lead to uncertainty about our ability to continue as a going concern.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We have announced that we are considering strategic alternatives in order to maximize stockholder value. We may not be able
to identify or consummate a suitable transaction as a result of this review.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We have been involved in multiple legal and governmental proceedings, and may in the future be involved in proceedings, relating
to the commercial activities of our predecessor that could adversely affect our financial condition and our business.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We are dependent on technologies we license, and if we lose the right to license such technologies or we fail to license new
technologies in the future, our ability to develop new products would be harmed, and if we fail to meet our obligations under our
license agreements, we may lose the ability to develop our product candidates.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We are currently a clinical-stage biopharmaceutical company with product candidates in clinical development. If we are unable
to successfully develop and commercialize product candidates or experiences significant delays in doing so, our business may be
materially harmed.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our future success is dependent on the regulatory approval of our product candidates.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For additional information related to our business and operations,
please refer to the reports incorporated herein by reference, including our <A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/sls-20191231x10k.htm" STYLE="-sec-extract: exhibit">Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the SEC on March 13, 2020</A>, or the 2019 Form 10-K, our <A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047820000014/sls-20200331x10q.htm" STYLE="-sec-extract: exhibit">Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 as filed with the SEC on May 14, 2020</A>, or the 2020 Form 10-Q, and our Current Reports on Form 8-K as filed
with the SEC, as described in the section entitled &ldquo;<I>Incorporation of Documents by Reference</I>&rdquo; beginning on page
14 of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We were incorporated on April 3, 2006 in Delaware as Argonaut
Pharmaceuticals, Inc. On November 28, 2006, we changed our name to RXi Pharmaceuticals Corporation and began operations in January
2007. On September 26, 2011, we changed our name to Galena Biopharma, Inc. In December, 2017, we completed the business combination
with the privately held Bermuda exempted company, Sellas Life Sciences Group Ltd., or Private SELLAS, which we refer to throughout
the registration statement of which this prospectus forms a part as the &ldquo;Merger.&rdquo; As a result of the Merger, our business
is now substantially comprised of the business of Private SELLAS. Upon completion of the Merger, we changed our name from &ldquo;Galena
Biopharma, Inc.&rdquo; to &ldquo;SELLAS Life Sciences Group, Inc.,&rdquo; our common stock began trading on The Nasdaq Capital
Market under a new ticker symbol &ldquo;SLS&rdquo; on January 2, 2018 and our financial statements became those of Private SELLAS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our principal executive offices are located at 15 West 38<SUP>th</SUP>
Street, 10<SUP>th</SUP> Floor, New York, NY 10018, and our phone number is (917) 438-4353. Our website address is www.sellaslife.com.
The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our
website address in this prospectus solely as an inactive textual reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Registered Direct Offering of Common Stock and Concurrent
Private Placement of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 9, 2020, we entered into a Securities Purchase Agreement
(the &ldquo;Purchase Agreement&rdquo;) with certain investors named therein (the &ldquo;Investors&rdquo;), pursuant to which we
agreed to issue and sell, in a registered direct offering directly to the Investors (the &ldquo;Registered Offering&rdquo;), (i)
an aggregate of 1,189,000 shares (the &ldquo;Shares&rdquo;) of our common stock at an offering price of $3.9825 per share and (ii)
an aggregate of 448,800 pre-funded warrants exercisable for shares of common stock (the &ldquo;Pre-Funded Warrants&rdquo;) at an
offering price of $3.9725 per Pre-Funded Warrant, for gross proceeds of approximately $6.5 million before deducting the placement
agent fee and related offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In a concurrent private placement (the &ldquo;Private Placement&rdquo;
and together with the Registered Offering, the &ldquo;Offerings&rdquo;), we agreed to issue to the Investors who participated in
the Registered Offering warrants (the &ldquo;Warrants&rdquo; and collectively with the Shares and the Pre-Funded Warrants, the
 &ldquo;Securities&rdquo;) exercisable for an aggregate of 818,900 shares of common stock at an exercise price of $3.93 per share.
Each Warrant was immediately exercisable and will expire five and one-half years from the issuance date. The Warrants and the shares
of our common stock issuable upon the exercise of the Warrants were offered pursuant to the exemption provided in Section 4(a)(2)
under the Securities Act and Rule 506(b) promulgated thereunder. We closed such Offerings on January 13, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Securities offered by the selling stockholders</FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 55%; font-size: 10pt"><FONT STYLE="font-size: 10pt">818,900 shares.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Common Stock to be outstanding after this offering, assuming exercise of the Warrants issued pursuant to the Purchase Agreement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">7,536,800 shares.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Terms of the offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">The selling stockholders and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their shares covered hereby on The Nasdaq Capital Market or any other stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. See &ldquo;Plan of Distribution.&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">We may receive up to approximately $3.2 million in aggregate gross proceeds from cash exercises of the Warrants, based on the per share exercise price of the Warrants. Any proceeds we receive from the exercise of the Warrants will be used to advance our clinical programs and for general corporate purposes. See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">An investment in our securities involves a high degree of risk. See the section entitled &ldquo;<I>Risk Factors</I>&rdquo; beginning on page 5 of this prospectus and the similarly entitled sections in the documents incorporated by reference into this prospectus.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Nasdaq Capital Market symbol</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Our common stock is quoted on The Nasdaq Capital Market under the symbol &ldquo;SLS.&rdquo;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except as otherwise indicated herein, the number of shares of
our common stock to be outstanding after this offering is based on 6,717,900 shares of common stock outstanding as of March 31,
2020 and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>1,210,148 shares of Common Stock issuable as of the date hereof upon the exercise of common stock warrants outstanding as of
March 31, 2020 at a weighted average exercise price of $34.01 per share;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>193,520 shares of Common Stock issuable upon the exercise of stock options outstanding as of March 31, 2020 at a weighted-average
exercise price of $14.23 per share;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>170,000 shares of Common Stock issuable upon the vesting of restricted stock units outstanding as of March 31, 2020 at a weighted-average
grant date fair value of $1.89 per share;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>114,689 shares of Common Stock available for future issuance under the 2019 Equity Incentive Plan as of March 31, 2020; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>8,302 shares of Common Stock available for future issuance under the Employee Stock Purchase Plan as of March 31, 2020.&nbsp;</TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investing in our securities involves a high degree of risk.
Before investing in our securities, you should carefully consider the risks, uncertainties and assumptions contained in this prospectus
and discussed under the heading &ldquo;Risk Factors&rdquo; included in our most recent <A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/sls-20191231x10k.htm" STYLE="-sec-extract: exhibit">Annual Report on Form 10-K for the year ended December 31, 2019</A>, as revised or supplemented by subsequent filings, which are on file with the SEC and are incorporated
herein by reference, and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC
in the future. Our business, financial condition, results of operations and future growth prospects could be materially and adversely
affected by any of these risks. In these circumstances, the market price of our common stock could decline, and you may lose all
or part of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus and the documents incorporated by reference
into this prospectus include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended, that relate to future events or our future financial performance and involve
known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or
achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied
by these forward-looking statements. Words such as, but not limited to, &ldquo;anticipate,&rdquo; &ldquo;aim,&rdquo; &ldquo;believe,&rdquo;
 &ldquo;contemplate,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;design,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
 &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;predict,&rdquo; &ldquo;poise,&rdquo; &ldquo;project,&rdquo;
 &ldquo;potential,&rdquo; &ldquo;suggest,&rdquo; &ldquo;should,&rdquo; &ldquo;strategy,&rdquo; &ldquo;target,&rdquo; &ldquo;will,&rdquo;
 &ldquo;would,&rdquo; and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify
forward-looking statements, although not all forward-looking statements contain these identifying words. Although we believe that
we have a reasonable basis for each forward-looking statement contained in this prospectus and incorporated by reference into this
prospectus, we caution you that these statements are based on our projections of the future that are subject to known and unknown
risks and uncertainties and other factors that may cause our actual results, level of activity, performance or achievements expressed
or implied by these forward-looking statements, to differ. The section in this prospectus entitled &ldquo;<I>Risk Factors</I>&rdquo;
and the sections in our periodic reports, including the 2019 Form 10-K entitled &ldquo;Business,&rdquo; and in the 2019 Form 10-K
and the 2020 Form 10-Q entitled &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations,&rdquo;
as well as other sections in this prospectus and the documents or reports incorporated by reference into this prospectus, discuss
some of the factors that could contribute to these differences. These forward-looking statements include, among other things, statements
about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the extent to which our business may be adversely affected by the recent COVID-19 outbreak;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our projected financial position and estimated cash burn rate;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our estimates regarding expenses, future revenues and capital requirements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to continue as a going concern;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our need to raise substantial additional capital to fund our operations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the success, cost and timing of our clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our dependence on third parties in the conduct of our clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to obtain the necessary regulatory approvals to market and commercialize our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the potential that results of preclinical and clinical trials indicate our current product candidates or any future product
candidates we may seek to develop are unsafe or ineffective;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the results of market research conducted by us or others;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to obtain and maintain intellectual property protection for our current product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to
enforce or protect our intellectual property rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possibility that a third party may claim we have infringed, misappropriated or otherwise violated their intellectual property
rights and that we may incur substantial costs and be required to devote substantial time defending against these claims;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our reliance on third-party suppliers and manufacturers;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the success of competing therapies and products that are or become available;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to expand our organization to accommodate potential growth and our ability to retain and attract key personnel;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the potential for us to incur substantial costs resulting from product liability lawsuits against us and the potential for
these product liability lawsuits to cause us to limit our commercialization of our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>market acceptance of our product candidates, the size and growth of the potential markets for our current product candidates
and any future product candidates we may seek to develop, and our ability to serve those markets; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the successful development of our commercialization capabilities, including sales and marketing capabilities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our current product candidates are undergoing clinical development
and have not been approved by the FDA or the European Commission. These product candidates have not been, nor may they ever be,
approved by any regulatory agency or competent authorities nor marketed anywhere in the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may not actually achieve the plans, intentions or
expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking
statements. Forward-looking statements should be regarded solely as our current plans, estimates and beliefs. We have
included important factors in the cautionary statements included in this document, particularly in the section entitled
 &ldquo;<I>Risk Factors</I>&rdquo; beginning on page 5 of this prospectus that we believe could cause actual results or events
to differ materially from the forward-looking statements that we make. Moreover, we operate in a very competitive and rapidly
changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can
we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any forward-looking statements we may make. Given these risks and
uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary statement. Our forward-looking statements do not reflect the
potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. You should
read this prospectus and the documents that we have filed as exhibits to this prospectus and incorporated by reference herein
completely and with the understanding that our actual future results may be materially different from the plans, intentions
and expectations disclosed in the forward-looking statements we make. The forward-looking statements contained in this
prospectus are made as of the date of this prospectus and we do not assume any obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will not receive any of the proceeds from the sale of securities
by the selling stockholders pursuant to this prospectus. We may receive up to approximately $3.2 million in aggregate gross proceeds
from cash exercises of the Warrants, based on the per share exercise price of the Warrants. Any proceeds we receive from the exercise
of the Warrants will be used to advance our clinical programs and for general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A><B>SELLING STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The shares of common stock being offered
by the selling stockholders are those issuable upon the exercise of the Warrants. For additional information regarding the issuance
of these securities, see &ldquo;Prospectus Summary&mdash;Registered Direct Offering of Common Stock and Concurrent Private Placement
of Warrants&rdquo; on page 3 of this prospectus. We are registering the shares of common stock issuable upon exercise of the
Warrants in order to permit the selling stockholders to offer the shares for resale from time to time. Except for the ownership
of the Warrants, the transactions contemplated pursuant to the Purchase Agreement and other financings completed by us, the selling
stockholders have not had any material relationship with us within the past three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth certain
information with respect to each selling stockholder, including (i) the shares of our common stock beneficially owned by the selling
stockholder prior to this offering, (ii) the number of shares being offered by the selling stockholder pursuant to this prospectus
and (iii) the selling stockholder&rsquo;s beneficial ownership after completion of this offering. The registration of the shares
of common stock issuable to the selling stockholders upon the exercise of the Warrants does not necessarily mean that the selling
stockholders will sell all or any of such shares, but the number of shares and percentages set forth in the final two columns below
assume that all shares of common stock being offered by the selling stockholders are sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The table is based on information supplied
to us by the selling stockholders, with beneficial ownership and percentage ownership determined in accordance with the rules and
regulations of the SEC, and includes voting or investment power with respect to shares of stock. This information does not necessarily
indicate beneficial ownership for any other purpose. In computing the number of shares beneficially owned by a selling stockholder
and the percentage ownership of that selling stockholder, shares of common stock subject to warrants held by that selling stockholder
that are exercisable within 60 days after May 29, 2020, are deemed outstanding. Such shares, however, are not deemed outstanding
for the purposes of computing the percentage ownership of any other person. The percentage of beneficial ownership after this offering
is based on 6,717,900 shares of common stock outstanding on May 14, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus covers the resale of 818,900
shares of our common stock that may be sold or otherwise disposed of by the selling stockholders. Such shares are issuable to the
selling stockholders upon the exercise of the Warrants. The Warrants are immediately exercisable on the date of their issuance
and expire five and a half (5.5) years from the date they became exercisable. All of the Warrants have an exercise price of $3.93
per share. See &ldquo;Prospectus Summary &mdash;Registered Direct Offering of Common Stock and Concurrent Private Placement of
Warrants&rdquo; above for a complete description of the Warrants. The selling stockholders may sell all, some or none of their
shares in this offering, but the number of shares and percentages set forth in the final two columns below assume that all shares
of common stock being offered by the selling stockholders are sold. See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Selling</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Security Holder (1)</B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of Shares</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Beneficially</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Owned</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prior to Offering (2)</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of Shares<BR>
 of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Underlying Warrants Offered <BR>
Hereby (3)</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of Shares</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Beneficially Owned</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>After Offering (4)</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>% of Shares</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of Common</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Stock Beneficially Owned</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>After</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offering (4)</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: left">Anson Investments Master Fund LP (5)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">409,900</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">409,900</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">CVI Investments, Inc. (5)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">415,323</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">409,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,323</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">*</TD><TD>Less than one percent.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>This table and the information in the notes below are based upon information supplied by the selling stockholder, including
reports and amendments thereto filed with the SEC on Schedule 13D and Schedule 13G.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>The shares of common stock underlying warrants are convertible or exercisable within 60 days of May 29, 2020.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>The actual number of shares of common stock offered hereby and included in the registration statement of which this prospectus
forms a part includes, in accordance with Rule 416 under the Securities Act, such indeterminate number of additional shares of
our common stock as may become issuable in connection with any proportionate adjustment for any stock splits, stock combinations,
stock dividends, recapitalizations or similar events with respect to the common stock.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>Assumes the exercise in full of the warrants and sale of all warrant shares registered pursuant to this prospectus, although
the selling stockholders are under no obligation known to us to sell any shares of common stock at this time.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(5)</TD><TD STYLE="text-align: justify">Anson Advisors Inc and Anson Funds Management LP,
the Co-Investment Advisers of Anson Investments Master Fund LP (&ldquo;Anson&rdquo;), hold voting and dispositive power over the
Common Shares held by Anson. Bruce Winson is the managing member of Anson Management GP LLC, which is the general partner of Anson
Funds Management LP. Moez Kassam and Amin Nathoo are directors of Anson Advisors Inc. Mr. Winson, Mr. Kassam and Mr. Nathoo each
disclaim beneficial ownership of these Common Shares except to the extent of their pecuniary interest therein. The principal business
address of Anson is Walkers Corporate Limited, Cayman Corporate Centre, 27 Hospital Road, George Town, Grand Cayman KY1-9008,
Cayman Islands.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(6)</TD><TD STYLE="text-align: justify">Heights Capital Management, Inc., the authorized agent
of CVI Investments, Inc. (&ldquo;CVI&rdquo;), has discretionary authority to vote and dispose of the shares held by CVI and may
be deemed to be the beneficial owner of these shares. Martin Kobinger, in his capacity as Investment Manager of Heights Capital
Management, Inc., may also be deemed to have investment discretion and voting power over the shares held by CVI.&nbsp; Mr. Kobinger
disclaims any such beneficial ownership of the shares.&nbsp; CVI Investments, Inc. is affiliated with one or more FINRA member,
none of whom are currently expected to participate in the sale pursuant to the prospectus contained in the Registration Statement
of Shares purchased by the Investor in this Offering.&nbsp; The principal business address of Heights is PO Box 309GT, Ugland
House, South Church Street, George Town, Grand Cayman, Cayman Islands.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="a_007"></A><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each selling stockholder of the securities
and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered
hereby on The Nasdaq Capital Market or any other stock exchange, market or trading facility on which the securities are traded
or in private transactions. These sales may be at fixed or negotiated prices. A selling stockholder may use any one or more of
the following methods when selling securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion
of the block as principal to facilitate the transaction;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an exchange distribution in accordance with the rules of the applicable exchange;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>privately negotiated transactions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>settlement of short sales;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in transactions through broker-dealers that agree with the selling stockholders to sell a specified number of such securities
at a stipulated price per security;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a combination of any such methods of sale; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other method permitted pursuant to applicable law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The selling stockholders may also sell
securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Broker-dealers engaged by the selling stockholders
may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling
stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated,
but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary
brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction, a markup or markdown in compliance
with FINRA IM-2440.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In connection with the sale of the securities
or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions,
which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The selling stockholders
may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities
to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions
with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such
broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other
financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The selling stockholders and any broker-dealers
or agents that are involved in selling the securities may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the
Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any
profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities
Act. Each selling stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly
or indirectly, with any person to distribute the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company is required to pay certain
fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the
selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We agreed to keep this prospectus effective
until the earlier of (i) the date on which the securities may be resold by the selling stockholders without registration and without
regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance
with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of
the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect.
The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities
laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or
qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and
is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 2; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to applicable rules and
regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously
engage in market making activities with respect to the common stock for the applicable restricted period, as defined in
Regulation M, prior to the commencement of the distribution. In addition, the selling stockholders will be subject to
applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit
the timing of purchases and sales of the common stock by the selling stockholders or any other person. We will make copies of
this prospectus available to the selling stockholders and have informed them of the need to deliver a copy of this prospectus
to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_008"></A><B>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following description of our capital stock summarizes the
material terms and provisions of our common stock and our preferred stock. For the complete terms of our common stock, please refer
to our amended and restated certificate of incorporation and our amended and restated bylaws, each as amended to date, that are
incorporated by reference into the registration statement of which this prospectus is a part or may be incorporated by reference
into this prospectus. The terms of these securities may also be affected by the Delaware General Corporation Law, or the DGCL.
The summary below is qualified in its entirety by reference to our amended and restated certificate of incorporation and amended
and restated bylaws, each as in effect at the time of any offering of securities under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Our amended and restated
certificate of incorporation authorizes us to issue up to 350,000,000 shares of common stock, $0.0001 par value per share, and
5,000,000 shares of preferred stock, $0.0001 par value per share</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2020, there were:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>6,717,900 shares of common stock outstanding;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>193,520 shares of common stock issuable upon exercise of outstanding options;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>170,000 shares of common stock issuable upon settlement of outstanding RSUs; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>warrants outstanding for the purchase of an aggregate of 1,120,148 shares of common stock;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Voting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Each holder of our common
stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of
directors. Our amended and restated certificate of incorporation and amended and restated bylaws do not provide for cumulative
voting rights. Because of this absence of cumulative voting, the holders of a majority of the shares of common stock entitled to
vote in any election of directors can elect all the directors standing for election, if they should so choose</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Dividends</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Subject to preferences
that may be applicable to any then outstanding shares of preferred stock, holders of common stock are entitled to receive ratably
those dividends, if any, as may be declared from time to time by our board of directors out of legally available funds</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Liquidation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">In the event of our dissolution
or liquidation, holders of common stock will be entitled to share ratably in the net assets legally available for distribution
to stockholders after the payment of all our debts and other liabilities and the satisfaction of any preferential rights that may
be granted to the holders of any then outstanding shares of preferred stock</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Rights and Preferences</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Holders of common stock
have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to the
common stock. The rights, preferences, and privileges of the holders of common stock are subject to, and may be adversely affected
by, the rights of the holders of shares of any series of preferred stock</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Fully-paid</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">All of the outstanding
shares of our common stock are, and the shares of common stock issued upon the conversion of any securities convertible into our
common stock will be, fully paid and&nbsp;non-assessable.&nbsp;The shares of common stock offered by this prospectus or upon the
conversion of any preferred stock or debt securities or exercise of any warrants offered pursuant to this prospectus, when issued
and paid for, will also be, fully paid and non-assessable</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Under our amended and restated certificate
of incorporation, our board of directors has the authority, without further action by our stockholders, to issue up to 5,000,000
shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These
rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation
preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all
of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting
power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation.
In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change of control of
our company or other corporate action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 4; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The following summary of terms of our
preferred stock is not complete. You should refer to the provisions of our amended and restated certificate of incorporation and
amended and restated bylaws and the resolutions containing the terms of each class or series of the preferred stock which have
been or will be filed with the SEC at or prior to the time of issuance of such class or series of preferred stock and described
in the applicable prospectus supplement. The applicable prospectus supplement may also state that any of the terms set forth herein
are inapplicable to such series of preferred stock, provided that the information set forth in such prospectus supplement does
not constitute material changes to the information herein such that it alters the nature of the offering or the securities offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our board of directors will fix the
designations, voting powers, preferences and rights of the preferred stock of each series we issue under this prospectus, as well
as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will
file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports
that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock
we are offering. We will describe in the applicable prospectus supplement the terms of the series of preferred stock being offered,
including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the title and stated value;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 74.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the number of shares we are offering;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 74.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the liquidation preference per share;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 74.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the purchase price;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 74.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the dividend rate, period and payment date and method of calculation for dividends;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 74.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 74.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the procedures for any auction and remarketing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 74.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the provisions for a sinking fund;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 74.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the provisions for redemption or repurchase and any restrictions on our ability to exercise those redemption and repurchase
rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any listing of the preferred stock on any securities exchange or market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 74.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether the preferred stock will be convertible into our common stock or other securities, and the conversion rate or conversion
price, or how they will be calculated, and the conversion period;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 74.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether the preferred stock will be exchangeable into debt securities, and the exchange rate or exchange price, or how they
will be calculated, and the exchange period;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 74.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>voting rights of the preferred stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 74.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>preemptive rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 74.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>restrictions on transfer, sale or other assignment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 74.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether interests in the preferred stock will be represented by depositary shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 74.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a discussion of material or special U.S. federal income tax considerations applicable to the preferred stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 74.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind
up our affairs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 74.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any limitations on the issuance of any class or series of preferred stock ranking senior to or on parity with the series of
preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 74.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we issue shares of preferred stock under this prospectus,
they will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The DGCL provides that the holders of preferred stock will have
the right to vote separately as a class on any proposal involving fundamental changes in the rights of holders of such preferred
stock. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The issuance of our preferred stock could adversely affect the
voting power, conversion or other rights of holders of common stock and reduce the likelihood that such holders will receive dividend
payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring
or preventing a change in control of our company or other corporate action. Additionally, the issuance of preferred stock may have
the effect of decreasing the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of March 31, 2020, we had warrants outstanding to purchase </FONT>1,120,148 <FONT STYLE="font-family: Times New Roman, Times, Serif">shares
of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Possible Anti-Takeover Effects of Delaware Law and Our Certificate
of Incorporation and Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Provisions of the DGCL and our amended
and restated certificate of incorporation and amended and restated bylaws could make it more difficult to acquire our company by
means of a tender offer, a proxy contest or otherwise, or to remove incumbent officers and directors. These provisions, summarized
below, are expected to discourage certain types of coercive takeover practices and takeover bids that our board of directors may
consider inadequate and to encourage persons seeking to acquire control of our company to first negotiate with our board of directors.
We believe that the benefits of increased protection of our ability to negotiate with the proponent of an unfriendly or unsolicited
proposal to acquire or restructure our company outweigh the disadvantages of discouraging takeover or acquisition proposals because,
among other things, negotiation of these proposals could result in an improvement of their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Classified Board</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our amended and restated certificate
of incorporation and our amended and restated bylaws provide that our board of directors is divided into three classes. The directors
designated as Class&nbsp;I directors have terms expiring at the annual meeting of stockholders in 2020. The directors designated
as Class&nbsp;II directors will have terms expiring at the annual meeting of stockholders in 2021, and the directors designated
as Class&nbsp;III directors will have terms expiring at the annual meeting of stockholders in 2022. Directors for each class will
be elected at the annual meeting of stockholders held in the year in which the term for that class expires and thereafter will
serve for a term of three years. In order to more evenly divide the classes of directors, and consistent with our amended and
restated bylaws, John Varian has agreed that, if he is reelected at the 2020 annual meeting as a Class I director, he will resign
from his Class I director seat, and the Board will simultaneously appoint him to a newly created directorship in Class III. As
a result, Mr. Varian would be up for reelection with other Class III directors at the 2022 annual meeting, rather than with the
Class I directors at the 2023 annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">At any meeting of stockholders for the election of directors at which a quorum is present, the
election will be determined by a plurality of the votes cast by the stockholders entitled to vote at the election. Under the classified
board provisions, it would take at least two elections of directors for any individual or group to gain control of our board. Accordingly,
these provisions could discourage a third party from initiating a proxy contest, making a tender offer or otherwise attempting
to gain control of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Removal of Directors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our amended and restated bylaws provide
that our stockholders may only remove our directors with cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Amendment</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our amended and restated certificate
of incorporation and our amended and restated bylaws provide that the affirmative vote of the holders of at least 75% of our voting
stock then outstanding is required to amend certain provisions relating to the number, term, election and removal of our directors,
the filling of our board vacancies, stockholder notice procedures, the calling of special meetings of stockholders and the indemnification
of directors. Further, any amendments of our bylaws must be approved by our stockholders as our amended and restated certificate
of incorporation does not authorize our board of directors to amend our bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Size of Board and Vacancies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our amended and restated bylaws provide
that the number of directors on our board of directors is fixed exclusively by our board of directors. Newly created directorships
resulting from any increase in our authorized number of directors will be filled by a majority of our board of directors then in
office, provided that a majority of the entire board of directors, or a quorum, is present and any vacancies in our board of directors
resulting from death, resignation, retirement, disqualification, removal from office or other cause will be filled generally by
the majority vote of our remaining directors in office, even if less than a quorum is present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 6; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Special Stockholder Meetings</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our amended and restated certificate
of incorporation provides that only the Chairman of our board of directors, our Chief Executive Officer or our board of directors
pursuant to a resolution adopted by a majority of the total number of directors we would have if there were no vacancies may call
special meetings of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Stockholder Action by Unanimous Written Consent</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our amended and restated certificate
of incorporation expressly eliminates the right of our stockholders to act by written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Requirements for Advance Notification
of Stockholder Nominations and Proposals</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our amended and restated bylaws provide
advance notice procedures with respect to stockholder proposals and nomination of candidates for election as directors other than
nominations made by or at the direction of board of directors or a committee of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>No Cumulative Voting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The DGCL provides that stockholders
are denied the right to cumulate votes in the election of directors unless our certificate of incorporation provides otherwise.
Our amended and restated certificate of incorporation does not provide for cumulative voting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Undesignated Preferred Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The authority that is possessed by
our board of directors to issue preferred stock could potentially be used to discourage attempts by third parties to obtain control
of our company through a merger, tender offer, proxy contest, or otherwise by making it more difficult or costlier to obtain control
of our company. Our board of directors may issue preferred stock with voting rights or conversion rights that, if exercised, could
adversely affect the voting power of the holders of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Authorized but Unissued Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our authorized but unissued shares
of common stock and preferred stock will be available for future issuance without stockholder approval. We may use additional shares
for a variety of purposes, including future public offerings to raise additional capital, to fund acquisitions and as employee
compensation. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or
discourage an attempt to obtain control of our company by means of a proxy contest, tender offer, merger or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The above provisions may deter a hostile
takeover or delay a change in control or management of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Listing on The Nasdaq Capital Market</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our common stock is listed on The Nasdaq
Capital Market under the symbol &ldquo;SLS&rdquo;. On May 27, 2020, the closing price of our common stock was $3.60 per share.
As of May 27, 2020, we had approximately 26 stockholders of record.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The applicable prospectus supplement
will contain information, where applicable, as to other listing, if any, on The Nasdaq Capital Market or other securities exchange
of the preferred stock covered by such prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The transfer agent and
registrar for our capital stock is Computershare Trust Company, N.A. Its address is 250 Royall Street, Canton, MA 02021. Its telephone
number is (201)&nbsp;680-4503.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_009"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The validity of the securities offered hereby is being passed
upon for us by Mintz, Levin, Cohn, Ferris, Glovsky &amp; Popeo, P.C., New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our consolidated financial statements appearing in our <A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/sls-20191231x10k.htm" STYLE="-sec-extract: exhibit">Annual
Report on Form 10-K for the year ended December 31, 2019</A>, have been audited by Moss Adams LLP, an independent registered
public accounting firm, as stated in their report, which is incorporated herein by reference. Such consolidated financial
statements have been so incorporated in reliance upon the report of such firm (which report expresses an unqualified opinion
and includes an explanatory paragraph regarding the Company&rsquo;s going concern uncertainty) given upon their authority as
experts in accounting and  auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_011"></A><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a reporting company and file annual, quarterly and current
reports, proxy statements and other information with the SEC. We have filed with the SEC a registration statement on Form S-1 under
the Securities Act with respect to the offer and sale of our securities under this prospectus. This prospectus does not contain
all of the information set forth in the registration statement and the exhibits to the registration statement. For further information
with respect to us and the securities offered under this prospectus, we refer you to the registration statement and the exhibits
filed as a part of the registration statement. The SEC also maintains an Internet site that contains reports, proxy and information
statements and other information regarding issuers that file electronically with the SEC, including SELLAS Life Sciences Group,
Inc. The SEC&rsquo;s Internet site can be found at www.sec.gov. We maintain a website at www.sellaslife.com. Information found
on, or accessible through, our website is not a part of, and is not incorporated into, this prospectus, and you should not consider
it part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_012"></A><B>INCORPORATION OF DOCUMENTS BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The SEC allows us to incorporate by reference the information
we file with it, which means that we can disclose important information to you by referring you to another document that we have
filed separately with the SEC. You should read the information incorporated by reference because it is an important part of this
prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to
the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information
in this prospectus. We incorporate by reference into this prospectus and the registration statement of which this prospectus is
a part the information or documents listed below that we have filed with the SEC (Commission File No. 001-33958):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000110465920049860/tm2016499d1_def14a.htm" STYLE="-sec-extract: exhibit">our definitive proxy statement on Schedule 14A filed with the SEC on April 23, 2020;</A></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/sls-20191231x10k.htm" STYLE="-sec-extract: exhibit">our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 13, 2020;</A></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047820000014/sls-20200331x10q.htm" STYLE="-sec-extract: exhibit">our Quarterly Report on Form 10-Q for the three months ended March 31, 2020, filed with the SEC on May 14, 2020;</A></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our Current Reports on Form 8-K, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000110465920002021/tm201472d1_8k.htm" STYLE="-sec-extract: exhibit">January 7, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000110465920002807/tm201678d1_8k.htm" STYLE="-sec-extract: exhibit">January 10, 2020</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047820000009/sls-20200313x8xk.htm" STYLE="-sec-extract: exhibit">March 13, 2020</A>; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095013508000652/b684708ae8va12b.htm" STYLE="-sec-extract: exhibit">the description of our common stock set forth in our registration statement on Form 8-A, filed with the SEC on <FONT STYLE="font-family: Symbol"></FONT>February 8, 2008, as amended on February 12, 2008, including any further amendments thereto or reports filed for the purposes of updating this description.</A></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also incorporate by reference any future filings (other than
current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items
unless such Form 8-K expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the
Exchange Act, including those made after the date of the initial filing of the registration statement of which this prospectus
is a part and prior to effectiveness of such registration statement, until we file a post-effective amendment that indicates the
termination of the offering of the common stock made by this prospectus and will become a part of this prospectus from the date
that such documents are filed with the SEC. Information in such future filings updates and supplements the information provided
in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information
in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent
that statements in the later filed document modify or replace such earlier statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will furnish without charge to each person, including any
beneficial owner, to whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents incorporated
by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated
by reference into such documents. You should direct any requests for documents to SELLAS Life Sciences Group, Inc., Attention:
Corporate Secretary, 15 West 38<SUP>th</SUP> Street, 10th Floor, New York, New York 10018. Our phone number is (917) 438-4353.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should rely only on information contained in, or
incorporated by reference into, this prospectus and any prospectus supplement. We have not authorized anyone to provide you
with information different from that contained in this prospectus or incorporated by reference into this prospectus. We are
not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in
which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such
offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Split-Segment; Name: 4 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.65in"><B>Item 13.</B></TD><TD><B>Other Expenses of Issuance and Distribution.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the expenses to be incurred in
connection with the offering described in this Registration Statement, other than underwriting discounts and commissions, all which
will be paid by the Registrant. All amounts are estimates except the Securities and Exchange Commission, or SEC, registration fee
and the Financial Industry Regulatory Authority, Inc., filing fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%"><FONT STYLE="font-size: 10pt">Securities and Exchange Commission registration fee</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: left; width: 9%"><FONT STYLE="font-size: 10pt">417.73</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Accountant&rsquo;s fees and expenses</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">15,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Legal fees and expenses</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left">30,000</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Miscellaneous</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">10,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Total expenses</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: left">45,417.73</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.65in"><B>Item 14.</B></TD><TD><B>Indemnification of Directors and Officers.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As permitted by Section 102 of the Delaware General Corporation
Law, we have adopted provisions in our amended and restated certificate of incorporation and amended and restated bylaws, each
as amended, which limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as a
director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business
judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable
to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any breach of the director&rsquo;s duty of loyalty to us or our stockholders;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any transaction from which the director derived an improper personal benefit.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These limitations of liability do not affect the availability
of equitable remedies such as injunctive relief or rescission. Our amended and restated certificate of incorporation also authorizes
us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As permitted by Section 145 of the Delaware General Corporation
Law, our amended and restated bylaws, as amended, provide that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we may indemnify our directors, officers and employees to the fullest extent permitted by the Delaware General Corporation
Law, subject to limited exceptions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we may advance expenses to our directors, officers and employees in connection with a legal proceeding to the fullest extent
permitted by the Delaware General Corporation Law, subject to limited exceptions; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the rights provided in our bylaws are not exclusive.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our amended and restated certificate of incorporation and bylaws,
each as amended, which are filed as Exhibits 3.1 and 3.3, provide for the indemnification provisions described above and elsewhere
herein. We have entered into separate indemnification agreements with our directors and officers that may be broader than the specific
indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements generally require
us, among other things, to indemnify our officers and directors against liabilities that may arise by reason of their status or
service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also
generally require us to advance any expenses incurred by the directors or officers as a result of any proceeding against them as
to which they could be indemnified. In addition, we have purchased a policy of directors&rsquo; and officers&rsquo; liability insurance
that insures our directors and officers against the cost of defense, settlement or payment of a judgment in some circumstances.
These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of our
officers and directors for liabilities, including reimbursement of expenses incurred, arising under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have entered into indemnification agreements with our directors
and executive officers, in addition to the indemnification provided for in our amended and restated certificate of incorporation
and amended and restated bylaws, and intend to enter into indemnification agreements with any new directors and executive officers
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have purchased and currently intend to maintain insurance
on behalf of each and every person who is or was a director or officer of our company against any loss arising from any claim asserted
against him or her and incurred by him or her in any such capacity, subject to certain exclusions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.65in"><B>Item 15.</B></TD><TD><B>Recent Sales of Unregistered Securities. </B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since March 31, 2017, the registrant has issued unregistered
securities to the persons, as described below. None of these transactions involved any underwriters, underwriting discounts or
commissions, except as specified below, or any public offering, and the registrant believes that, except as set forth below, each
transaction was exempt from the registration requirements of the Securities Act of 1933 by virtue of Section 4(2) or Section 3(a)(10)
thereof and/or Regulation D or Regulation S promulgated thereunder. All recipients had adequate access, though their relationships
with the registrant, to information about the registrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a)</TD><TD>In July 2017, the registrant entered into a binding settlement term sheet, pursuant to which the registrant agreed to pay a
portion of the settlement agreement ($1,250,000) in unrestricted shares of its common stock, which valuation will be based on the
volume-weighted average closing price for the 20 trading days immediately preceding the day before the transfer of the settlement
stock to the settlement fund pursuant to the terms and conditions of the settlement. Such shares were issued in June 2018.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b)</TD><TD>In February-May 2018, the registrant issued an aggregate of 1,092 shares of its common stock in exchange for the surrender
and cancellation of warrants to acquire 2,433 shares of its common stock, and $1.0 million in convertible promissory notes in exchange
for the surrender and cancellation of warrants to acquire 8,253 shares of its common stock, pursuant to individual agreements with
nine accredited investors; the cancelled warrants were issued to the holders thereof in a February 2017 registered offering. In
April 2018, $0.8 million of outstanding principal and accrued interest of the convertible promissory notes was converted into 2,372
shares of common stock.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c)</TD><TD>In March 2018, the registrant entered into a purchase agreement providing for the sale and issuance of an aggregate of 10,700
shares of its 20% non-voting Series A Convertible Preferred Stock (or Series A) and warrants to acquire an aggregate of 27,672
shares of its common stock to seven accredited investors. The securities were issued in two tranches (in March 2018 and May 2018),
for aggregate gross proceeds of $10.7 million of cash. Cantor Fitzgerald &amp; Co. acted as placement agent and received a fee
equal to 7% of the gross proceeds received from U.S-based investors, as well as reimbursement for its actual, out-of-pocket accountable
expenses (including legal fees and expenses) incurred in connection with the private placement. In May 2018, 2,898 shares of Series
A were converted into 9,994 shares of common stock.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD>In March 2019, the registrant entered into a Warrant Exercise Agreement which (i) amends the warrants issued in July 2018 to
reduce the exercise price per share of such warrants and (ii) provides for the issuance of new warrants to purchase up to an aggregate
of approximately 76,000 shares of the registrant&rsquo;s common stock (the &ldquo;New Warrants&rdquo;). The New Warrants are exercisable
after the six-month anniversary of issuance and terminate on the five-year anniversary following the initial exercise date. The
New Warrants have an exercise price per share of $70.00.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">e)</TD><TD>In January 2020, the registrant entered into a securities purchase agreement pursuant to which the registrant agreed to issue
to investors who participated in a registered direct offering warrants (the &ldquo;Warrants&rdquo;) exercisable for an aggregate
of 818,900 shares of common stock at an exercise price of $3.93 per share. Each Warrant was immediately exercisable and will expire
five and one-half years from the issuance date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.65in"><B>Item 16.</B></TD><TD><B>Exhibits and Financial Statement Schedules.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: -27pt">See Exhibit Index following the
signature page to this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.65in"><B>Item 17.</B></TD><TD><B>Undertakings. </B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD>To include any prospectus required by Section 10(a)(3) of the Securities Act;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD>To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most
recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information
set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered
(if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or
high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant
to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate
offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD>To include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">provided, however, that paragraphs (a)(1)(i), (ii), and (iii)
of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained
in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities
Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
at the termination of the offering.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution
of the securities:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned registrant undertakes that in a primary offering
of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used
to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities
to such purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD>Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant
to Rule 424;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD>Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred
to by the undersigned registrant;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD>The portion of any other free writing prospectus relating to the offering containing material information about the undersigned
registrant or its securities provided by or on behalf of the undersigned registrant; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(iv)</TD><TD>Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned registrant hereby undertakes that, for purposes
of determining any liability under the Securities Act, each filing of the registrant&rsquo;s annual report pursuant to section
13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&rsquo;s
annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration
statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers, and controlling persons of the registrant pursuant to the foregoing provisions,
or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned registrant hereby undertakes that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed
as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant
pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement
as of the time it was declared effective.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of these
securities at that time shall be deemed to be the initial bona fide offering.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act of 1933,
the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized
in the city of New York, New York, on this May 29, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SELLAS LIFE SCIENCES GROUP, INC.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Angelos M. Stergiou</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: </FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Angelos M. Stergiou, M.D., Sc.D., h.c.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: </FONT></TD>
<TD STYLE="font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="poa"></A>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We, the undersigned officers and directors
of SELLAS Life Sciences Group, Inc., hereby severally constitute and appoint Angelos M. Stergiou and John Burns, and each of them
singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in
the capacities indicated below, the registration statement on Form S-1 filed herewith, and any and all pre-effective and post-effective
amendments to said registration statement, and any registration statement filed pursuant to Rule 462(b) under the Securities Act
of 1933, as amended, in connection with the registration under the Securities Act of 1933, as amended, of equity securities of
the Company, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith,
with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and
perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes
as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their
substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the requirements of the Securities
Act of 1933, this Registration Statement on Form S-1 has been signed below by the following persons in the capacities and on the
dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="padding-top: 2pt; white-space: nowrap; vertical-align: bottom; text-align: center; padding-bottom: 2pt; width: 40%"><FONT STYLE="font-size: 10pt"><B>Signature</B></FONT></TD>
<TD STYLE="padding-top: 2pt; vertical-align: top; text-align: center; padding-bottom: 2pt; width: 2%">&nbsp;</TD>
<TD STYLE="padding-top: 2pt; vertical-align: bottom; text-align: center; padding-bottom: 2pt; width: 40%"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
<TD STYLE="padding-top: 2pt; vertical-align: top; text-align: center; padding-bottom: 2pt; width: 2%">&nbsp;</TD>
<TD STYLE="padding-top: 2pt; vertical-align: bottom; text-align: center; padding-bottom: 2pt; width: 16%"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 2pt; border-bottom: Black 1pt solid; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">/s/ Angelos M. Stergiou</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt">President, Chief Executive Officer and Director<BR>
 (Principal Executive and Financial Officer)</TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">May 29, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Angelos M. Stergiou, M.D., Sc.D., h.c.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 2pt; padding-bottom: 2pt">&nbsp;</TD></TR>
<TR>
<TD STYLE="padding-top: 2pt; border-bottom: Black 1pt solid; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">/s/ John Burns</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; vertical-align: top; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; vertical-align: top; padding-bottom: 2pt">Vice President, Finance and Corporate Controller<BR>
 (Interim Principal Accounting Officer)</TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; vertical-align: top; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; vertical-align: top; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">May 29, 2020</FONT></TD></TR>
<TR>
<TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">John Burns, C.P.A.</FONT></TD></TR>
<TR>
<TD STYLE="padding-top: 2pt; padding-bottom: 2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 2pt; border-bottom: Black 1pt solid; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">/s/ Jane Wasman</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Chair of the Board of Directors</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">May 29, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Jane Wasman</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 2pt; padding-bottom: 2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 2pt; border-bottom: Black 1pt solid; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">/s/ David A. Scheinberg</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">May 29, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">David A. Scheinberg, M.D., Ph.D.</FONT></TD></TR>
<TR>
<TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="padding-top: 2pt; vertical-align: top; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="padding-top: 2pt; vertical-align: top; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="padding-top: 2pt; vertical-align: top; padding-bottom: 2pt">&nbsp;</TD>
<TD STYLE="padding-top: 2pt; vertical-align: top; padding-bottom: 2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 2pt; border-bottom: Black 1pt solid; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">/s/ Robert L. Van Nostrand</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">May 29, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Robert L. Van Nostrand</FONT></TD></TR>
<TR>
<TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="padding-top: 2pt; vertical-align: top; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="padding-top: 2pt; vertical-align: top; padding-bottom: 2pt">&nbsp;</TD>
<TD STYLE="padding-top: 2pt; vertical-align: top; padding-bottom: 2pt">&nbsp;</TD>
<TD STYLE="padding-top: 2pt; vertical-align: top; padding-bottom: 2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 2pt; border-bottom: Black 1pt solid; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">/s/ John Varian</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD ROWSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">May 29, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">John Varian</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 5 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exhibits listed
below are filed as part of or incorporated by reference into this Registration Statement on Form S-1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; width: 10%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Number</B></P></TD>
    <TD STYLE="width: 62%; border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD>
    <TD STYLE="width: 7%; border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><FONT STYLE="font-size: 10pt"><B>Form</B></FONT></TD>
    <TD STYLE="width: 6%; border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="width: 15%; border: black 1pt solid; padding: 1.5pt"><FONT STYLE="font-size: 10pt"><B>Filing Date</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517250556/d434413dex21.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">2.1^</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517250556/d434413dex21.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Agreement and Plan of Merger, dated as of August 7, 2017, by and among the Registrant, Galena Bermuda Merger Sub, Ltd., Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc. and SELLAS Life Sciences Group Ltd, as amended (included as Annex A to the proxy statement/prospectus/consent solicitation statement)</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517250556/d434413dex21.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517250556/d434413dex21.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">2.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517250556/d434413dex21.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">August 8, 2017</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.1</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Composite Amended and Restated Certificate of Incorporation of the Registrant (formerly, Galena Biopharma, Inc.), amended as of December 27, 2017</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.2</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">March 12, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000110465919060564/tm1921505d2_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.3</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000110465919060564/tm1921505d2_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000110465919060564/tm1921505d2_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000110465919060564/tm1921505d2_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000110465919060564/tm1921505d2_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">November 6, 2019</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex33.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.4</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex33.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amended and Restated By-Laws of the Registrant</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex33.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex33.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.3</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex33.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">January 5, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.1**</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Common Stock Certificate</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311035465/b86058exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.2 </FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311035465/b86058exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Contingent Value Rights Agreement among the Registrant (formerly RXi Pharmaceuticals Corporation), Computershare Trust Company, N.A., Computershare Inc., and Robert E Kennedy, dated April 13, 2011</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311035465/b86058exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311035465/b86058exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311035465/b86058exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 14, 2011</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.3</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">First Amendment to Contingent Value Rights Agreement among the Registrant (formerly RXi Pharmaceuticals Corporation), Computershare Trust Company, N.A., Computershare Inc., and Robert E Kennedy, dated February 15, 2012</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.2</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">March 28, 2012</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.4</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Registration Rights Agreement dated May 10, 2016 between the Registrant and Purchasers</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-Q</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.3</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">May 10, 2016</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex42.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.5</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex42.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Series A Common Stock Purchase Warrant assigned to JGB (Cayman) Newton Ltd. dated May 10, 2016</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex42.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-Q</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex42.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.2</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex42.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">May 10, 2016</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex43.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.6</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex43.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Series B Common Stock Purchase Warrant assigned to JGB (Cayman) Newton Ltd. dated May 10, 2016</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex43.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-Q</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex43.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.3</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex43.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">May 10, 2016</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.7</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Subsidiary Guarantee dated May 10, 2016 between the Registrant and JGB Collateral LLC</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-Q</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.2</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">May 10, 2016</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-104.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.8</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-104.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Security Agreement dated May 10, 2016 between the Registrant and JGB Collateral LLC</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-104.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-Q</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-104.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.4</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-104.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">May 10, 2016</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000146/gale-20160823xex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.9</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000146/gale-20160823xex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amended and Restated 9% Original Issue Discount Senior Secured Debenture Due November 10, 2018, issued to JGB (Cayman) Newton Ltd. as of August 22, 2016</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000146/gale-20160823xex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000146/gale-20160823xex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000146/gale-20160823xex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">August 23, 2016</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000045/gale-20170710xex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.10</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000045/gale-20170710xex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amendment Agreement, dated as of July 10, 2017, by and between JGB Cayman (Newton) Ltd. and the Registrant with respect to the 9% Original Issue Discount Senior Secured Convertible Debenture in the Original Issue Amount of $25,350,000 Issued and Sold to JGB Cayman (Newton) Ltd. by the Registrant </FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000045/gale-20170710xex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000045/gale-20170710xex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000045/gale-20170710xex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">July 11, 2017</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517250556/d434413dex103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.11</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517250556/d434413dex103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Consent, dated as of August 7, 2017, made by JGB (Cayman) Newton Ltd., in favor of the Registrant</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517250556/d434413dex103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517250556/d434413dex103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.3</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517250556/d434413dex103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">August 8, 2017</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312513211191/d515003dex107.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.12</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312513211191/d515003dex107.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of warrants granted on May 8, 2013 under the Loan and Security Agreement</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312513211191/d515003dex107.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-Q</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312513211191/d515003dex107.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.7</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312513211191/d515003dex107.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">May
    9, 2013</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047813000024/exhibit41-warrantagreement.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.13</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047813000024/exhibit41-warrantagreement.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Warrant Agreement by and among the Registrant, Computershare Inc. and Computershare Trust Company, N.A.</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047813000024/exhibit41-warrantagreement.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047813000024/exhibit41-warrantagreement.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047813000024/exhibit41-warrantagreement.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">September 18, 2013</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047815000037/gale-20150630xex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.14</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047815000037/gale-20150630xex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant Agreement, dated as of March 18, 2015, by and among the Registrant, Computershare, Inc. and Computershare Trust Company, N.A.</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047815000037/gale-20150630xex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-Q</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047815000037/gale-20150630xex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047815000037/gale-20150630xex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">August 6, 2015</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312516423538/d106844dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.15</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312516423538/d106844dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Warrant Agreement by and among the Registrant, Computershare Inc. and Computershare Trust Company, N.A.</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312516423538/d106844dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312516423538/d106844dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312516423538/d106844dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">January 7, 2016</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312516643945/d174442dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.16</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312516643945/d174442dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Warrant, issued by the Registrant to the Investors on July 13, 2016</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312516643945/d174442dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312516643945/d174442dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312516643945/d174442dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">July 8, 2016</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000011/a201702088k41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.17</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000011/a201702088k41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Warrant Agreement, including the Form of Warrant, issued by the Registrant to the Investors on February 13, 2017</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000011/a201702088k41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000011/a201702088k41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000011/a201702088k41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">February 10, 2017</FONT></A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; border: black 1pt solid; padding: 1.5pt; width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex105.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.23</FONT></A></TD>
    <TD STYLE="vertical-align: top; width: 62%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex105.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant issued to EQC Private Markets SAC Fund Ltd &ndash; EQC Biotech Sely I Fund</FONT></A></TD>
    <TD STYLE="width: 7%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex105.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="width: 6%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex105.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.5</FONT></A></TD>
    <TD STYLE="width: 15%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex105.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">January 5, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1073.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.18</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1073.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant Exchange Agreement by and between the Registrant and CVI Investments, Inc., dated February 6, 2018</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1073.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1073.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.73</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1073.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1074.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.19</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1074.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Promissory Note by and between the Registrant and CVI Investments, Inc., dated February 6, 2018</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1074.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1074.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.74</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1074.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1075.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.20</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1075.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant Exchange Agreement by and between the Registrant and Anson Investments Master Fund LP, dated February 7, 2018</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1075.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1075.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.75</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1075.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1076.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.21</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1076.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant Exchange Agreement by and between the Registrant, Sabby Healthcare Master Fund Ltd and Sabby Volatility Warrant Master Fund Ltd, dated February 8, 2018</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1076.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1076.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.76</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1076.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1077.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.22</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1077.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant Exchange Agreement by and between the Registrant and Hudson Bay Master Fund Agreement, dated February 9, 2018</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1077.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1077.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.77</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1077.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1078.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.23</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1078.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Promissory Note by and between the Registrant and Hudson Bay Master Fund Agreement, dated February 9, 2018</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1078.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1078.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.78</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1078.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1079.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.24</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1079.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant Exchange Agreement by and between the Registrant and Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, dated February 13, 2018</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1079.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1079.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.79</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1079.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1080.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.25</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1080.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Promissory Note by and between the Registrant and Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, dated February 13, 2018</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1080.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1080.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.80</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1080.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1081.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.26</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1081.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant Exchange Agreement by and between the Registrant and Lincoln Park Capital LLC, dated February 14, 2018</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1081.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1081.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.81</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1081.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1082.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.27</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1082.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant Exchange Agreement by and between the Registrant and Empery Asset Master, Ltd., dated February 21, 2018</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1082.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1082.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.82</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1082.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1083.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.28</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1083.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant Exchange Agreement by and between the Registrant and Empery Tax Efficient, LP, dated February 21, 2018</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1083.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1083.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.83</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1083.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1084.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.29</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1084.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant Exchange Agreement by and between the Registrant and Empery Tax Efficient II, LP, dated February 21, 2018</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1084.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1084.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.84</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1084.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1085.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.30</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1085.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Promissory Note by and between the Registrant and Empery Asset Master, Ltd., dated February 21, 2018</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1085.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1085.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.85</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1085.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1086.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.31</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1086.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Promissory Note by and between the Registrant and Empery Tax Efficient, LP, dated February 21, 2018</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1086.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1086.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.86</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1086.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1087.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.32</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1087.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Promissory Note by and between the Registrant and Empery Tax Efficient II, LP, dated February 21, 2018</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1087.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1087.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.87</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1087.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.33</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant Agreement including form of accompanying Common Warrant as Exhibit B thereto, dated as of July 16, 2018, among the Registrant, Computershare, Inc., and Computershare Trust Company N.A.</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">July 18, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419034049/tv524889_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.34</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419034049/tv524889_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amendment to Warrant Agreement including form of accompanying Common Warrant as Exhibit B thereto, dated as of July 16, 2018, among the Registrant, Computershare, Inc., and Computershare Trust Company N.A.</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419034049/tv524889_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419034049/tv524889_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.2</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419034049/tv524889_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">July 9, 2019</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.35</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Pre-funded Warrant in connection with July 2018 public offering</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.2</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">July 18, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.36</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Warrant issued in exchange of Series A Preferred Stock in connection with July 2018 public offering</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.3</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">July 18, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000015/slsexhibit20180531-101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.37</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000015/slsexhibit20180531-101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant Exchange Agreement by and between the Registrant and Intracoastal Capital LLC dated May 25, 2018 (including as Exhibit A thereto, that certain Convertible Promissory Note by and between the Registrant and Intracoastal Capital LLC dated May 25, 2018)</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000015/slsexhibit20180531-101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000015/slsexhibit20180531-101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000015/slsexhibit20180531-101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">June 1, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047819000011/sls-20190305x8xkex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.38</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047819000011/sls-20190305x8xkex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of New Warrant issued in connection with Warrant Exercise Agreement dated March 6, 2019</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047819000011/sls-20190305x8xkex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047819000011/sls-20190305x8xkex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047819000011/sls-20190305x8xkex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">March 6, 2019</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419031351/tv523751_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.39</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419031351/tv523751_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant Agreement, including form of accompanying Common Warrant as Exhibit B thereto, dated as of June 18, 2019, among the Registrant, Computershare Inc., and Computershare Trust Company N.A.</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419031351/tv523751_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419031351/tv523751_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419031351/tv523751_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">June 18, 2019</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419031351/tv523751_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.40</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419031351/tv523751_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Pre-Funded Warrant in connection with June 2019 public offering</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419031351/tv523751_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419031351/tv523751_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.2</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419031351/tv523751_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">June 18, 2019</FONT></A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; border: black 1pt solid; padding: 1.5pt; width: 10%"><A HREF="tm2021170d1_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">5.1*</FONT></A></TD>
    <TD STYLE="vertical-align: top; width: 62%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="tm2021170d1_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</FONT></A></TD>
    <TD STYLE="width: 7%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 6%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 15%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">9.1</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Securities Purchase Agreement dated March 7, 2018 by and between the Registrant and certain investors</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">March 12, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000142/gale-20160822xex103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1**</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000142/gale-20160822xex103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">The Registrant&rsquo;s 2016 Incentive Plan effective as of July 14, 2016</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000142/gale-20160822xex103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000142/gale-20160822xex103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.3</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000142/gale-20160822xex103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">August 22, 2016</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047815000037/gale-20150630xex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.2**</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047815000037/gale-20150630xex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form Incentive Stock Option granted under the Registrant&rsquo;s 2016 Incentive Plan</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047815000037/gale-20150630xex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-Q</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047815000037/gale-20150630xex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047815000037/gale-20150630xex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">August 8, 2015</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047815000037/gale-20150630xex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.3**</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047815000037/gale-20150630xex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form Nonstatutory Stock Option granted under the Registrant&rsquo;s 2016 Incentive Plan</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047815000037/gale-20150630xex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-Q</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047815000037/gale-20150630xex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.2</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047815000037/gale-20150630xex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">August 8, 2015</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1061.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.4**</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1061.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">SELLAS Life Sciences Group, Ltd Stock Incentive Plan #1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1061.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">S-4/A</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1061.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.61</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1061.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">October 30, 2017</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1063.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.5**</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1063.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Restricted Stock Unit Grant and Agreement under SELLAS Life Sciences Group Ltd Stock Incentive Plan #1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1063.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">S-4/A</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1063.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.63</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1063.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">October 30, 2017</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex1010.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.6**</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex1010.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">2017 Equity Incentive Plan of the Registrant</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex1010.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex1010.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.10</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex1010.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">January 5, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex1011.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.7**</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex1011.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">2017 Employee Stock Purchase Plan of the Registrant</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex1011.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex1011.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.11</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex1011.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">January 5, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518088034/d538010dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.8**</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518088034/d538010dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Stock Option Grant Notice and Option Agreement under the 2017 Equity Incentive Plan.</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518088034/d538010dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518088034/d538010dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.2</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518088034/d538010dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">March 19, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex109.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.9**</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex109.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Restricted Stock Unit Grant and Agreement under the 2017 Equity Incentive Plan.</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex109.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex109.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.9</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex109.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1053.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.10**</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1053.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Employment Agreement by and between SELLAS Life Sciences Group AG and Angelos Stergiou, effective September 1, 2016</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1053.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">S-4/A</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1053.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.53</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1053.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">October 30, 2017</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1054.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.11**</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1054.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Employment Agreement by and between SELLAS Life Sciences Group AG and Gregory Torre, effective September 1, 2016</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1054.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">S-4/A</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1054.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.54</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1054.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">October 30, 2017</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1055.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.12**</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1055.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Employment Agreement by and between SELLAS Life Sciences Group AG and Nicholas Sarlis, effective September 19, 2016</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1055.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">S-4/A</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1055.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.55</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1055.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">October 30, 2017</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1056.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.13**</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1056.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Employment Agreement by and between SELLAS Life Sciences Group Ltd and Aleksey Krylov, dated October 24, 2017</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1056.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">S-4/A</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1056.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.56</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1056.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">October 30, 2017</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1057.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.14**</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1057.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Retention Agreement Letter by and between SELLAS Life Sciences Group Ltd and Gregory Torre, dated July 31, 2017</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1057.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">S-4/A</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1057.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.57</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1057.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">October 30, 2017</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1058.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.15**</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1058.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Retention Agreement Letter by and between SELLAS Life Sciences Group Ltd and Nicholas Sarlis, dated August 2, 2017</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1058.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">S-4/A</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1058.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.58</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1058.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">October 30, 2017</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518088034/d538010dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.16**</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518088034/d538010dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Letter Employment Agreement by and between SELLAS Life Sciences Group, Inc. and Barbara Wood, dated March 14, 2018</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518088034/d538010dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518088034/d538010dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518088034/d538010dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">March 19, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.17+</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Patent and Technology License Agreement, dated September 11, 2006, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-Q</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">August 15, 2011</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.18</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amendment No. 1 to Patent and Technology License Agreement, dated December 21, 2007, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-Q</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.2</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">August 15, 2011</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.19</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amendment No. 2 to Patent and Technology License Agreement, dated September 3, 2008, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-Q</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.3</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">August 15, 2011</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.20</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amendment No. 3 to Patent and Technology License Agreement, dated July 8, 2009, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-Q</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.4</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">August 15, 2011</FONT></A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; border: black 1pt solid; padding: 1.5pt; width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.21+</FONT></A></TD>
    <TD STYLE="vertical-align: top; width: 62%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amendment No. 4 to Patent and Technology License Agreement, dated February 11, 2010, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)</FONT></A></TD>
    <TD STYLE="width: 7%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-Q</FONT></A></TD>
    <TD STYLE="width: 6%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.5</FONT></A></TD>
    <TD STYLE="width: 15%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">August 15, 2011</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.22+</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amendment No. 5 to Patent and Technology License Agreement, dated January 10, 2011, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-Q</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.6</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">August 15, 2011</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.23</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Scientific Advisory Agreement between the Registrant (formerly Galena Biopharma, Inc.) and George E. Peoples, Ph.D., dated April 13, 2011</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-Q</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.10</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">August 15, 2011</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.24+</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Exclusive License Agreement, dated as of July 11, 2011, by and among The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., the Registrant (formerly Galena Biopharma, Inc.) and its wholly owned subsidiary, Apthera, Inc.</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-Q</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.12</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">August 15, 2011</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311085837/b88330exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.25+</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311085837/b88330exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Exclusive License Agreement, dated as of September 16, 2011, by and among The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Board of Regents of the University of Texas System, The University of Texas M. D. Anderson Cancer Center and the Registrant (formerly Galena Biopharma, Inc.)</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311085837/b88330exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311085837/b88330exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311085837/b88330exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">September 21, 2011</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: black 1pt solid; padding: 1.5pt; border-bottom: black 1pt solid"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex1045.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.26+</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex1045.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">License Agreement, effective as of April 30, 2009, between Kwangdong Pharmaceutical Co., Ltd. and Apthera, Inc.</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex1045.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex1045.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.45</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex1045.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">March 28, 2012</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: black 1pt solid; padding: 1.5pt; border-bottom: black 1pt solid"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex1046.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.27</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex1046.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amendment No. 1 to License Agreement, dated as of January 13, 2012, by and among Apthera, Inc., Kwangdong Pharmaceutical Co., Ltd., and the Registrant</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex1046.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex1046.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.46</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex1046.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">March 28, 2012</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: black 1pt solid; padding: 1.5pt; border-bottom: black 1pt solid"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312513103307/d459781dex1043.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.28+</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312513103307/d459781dex1043.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">License and Supply Agreement, effective December 3, 2012, by and between the Registrant and ABIC Marketing Limited, a subsidiary of Teva Pharmaceuticals</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312513103307/d459781dex1043.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312513103307/d459781dex1043.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.43</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312513103307/d459781dex1043.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">March 12, 2013</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: black 1pt solid; padding: 1.5pt; border-bottom: black 1pt solid"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047814000016/gale-20131231xex1036.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.29+</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047814000016/gale-20131231xex1036.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">License and Development Agreement, dated January 13, 2014, between the Registrant and Dr. Reddy&rsquo;s Laboratories, Ltd.</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047814000016/gale-20131231xex1036.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047814000016/gale-20131231xex1036.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.36</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047814000016/gale-20131231xex1036.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">March 17, 2014</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: black 1pt solid; padding: 1.5pt; border-bottom: black 1pt solid"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047814000016/gale-20131231xex1037.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.30+</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047814000016/gale-20131231xex1037.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Exclusive License Agreement, dated as of December 20, 2013, between Mills Pharmaceuticals, LLC and BioVascular, Inc.</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047814000016/gale-20131231xex1037.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047814000016/gale-20131231xex1037.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.37</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047814000016/gale-20131231xex1037.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">March 17, 2014</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: black 1pt solid; padding: 1.5pt; border-bottom: black 1pt solid"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000061/gale-20170911x8kex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.31</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000061/gale-20170911x8kex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amendment of the Exclusive License Agreement by and between Mills Pharmaceuticals, LLC and BioVascular, Inc.</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000061/gale-20170911x8kex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000061/gale-20170911x8kex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000061/gale-20170911x8kex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">September 11, 2017</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: black 1pt solid; padding: 1.5pt; border-bottom: black 1pt solid"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1064.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.32</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1064.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">License Agreement by and between SELLAS Life Sciences, Inc. and Madison Avenue Suites LLC, dated March 20, 2017</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1064.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">S-4/A</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1064.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.64</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1064.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">October 30, 2017</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: black 1pt solid; padding: 1.5pt; border-bottom: black 1pt solid"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1065.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.33+</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1065.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amended and Restated Exclusive License Agreement by and between SELLAS Life Sciences Group Ltd and Memorial Sloan Kettering Cancer Center, effective October 11, 2017</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1065.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">S-4/A</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1065.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.65</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1065.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">October 30, 2017</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: black 1pt solid; padding: 1.5pt; border-bottom: black 1pt solid"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex108.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.34</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex108.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Indemnity Agreement between the Registrant and each of its directors and executive officers</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex108.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex108.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.8</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex108.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">January 5, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000013/slsexhibit20180524-101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.35</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000013/slsexhibit20180524-101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">License Agreement made as of May 19, 2018 by and between the Registrant and 38th Street Suites LLC</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000013/slsexhibit20180524-101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000013/slsexhibit20180524-101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000013/slsexhibit20180524-101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">May 24, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000013/slsexhibit2018054-102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.36</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000013/slsexhibit2018054-102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Surrender Agreement made as of May 19, 2018 by and between the Registrant and Madison Avenue Suites LLC</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000013/slsexhibit2018054-102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000013/slsexhibit2018054-102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.2</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000013/slsexhibit2018054-102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">May 24, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000032/sls-20181105x8xkxexhibit101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.37</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000032/sls-20181105x8xkxexhibit101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Settlement Agreement between SELLAS Life Sciences Group, Inc. and individual named defendants, on the one hand, and JGB (Cayman) Newton, Ltd., JGB Collateral LLC, JGB Capital Offshore Ltd., JGB Partners L.P., and JGB Capital L.P., on the other hand, dated as of November 5, 2018</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000032/sls-20181105x8xkxexhibit101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000032/sls-20181105x8xkxexhibit101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000032/sls-20181105x8xkxexhibit101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">November 9, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.38</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Securities Purchase Agreement dated May 10, 2016 between the Registrant and Purchasers</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-Q</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">May 10, 2016</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000146/gale-20160823xex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.39</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000146/gale-20160823xex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amendment Agreement between the Registrant and JGB (Cayman) Newton Ltd. dated August 22, 2016.</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000146/gale-20160823xex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000146/gale-20160823xex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000146/gale-20160823xex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">August 23, 2016</FONT></A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; border: black 1pt solid; padding: 1.5pt; width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000009/a201702078k103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.40</FONT></A></TD>
    <TD STYLE="vertical-align: top; width: 62%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000009/a201702078k103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Waiver dated December 14, 2016 to the Securities Purchase Agreement, dated as of May 10, 2016, by and between Registrant and JGB (Cayman) Newton Ltd.</FONT></A></TD>
    <TD STYLE="width: 7%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000009/a201702078k103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="width: 6%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000009/a201702078k103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.3</FONT></A></TD>
    <TD STYLE="width: 15%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000009/a201702078k103.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">February 7, 2017</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000027/gale-20170403ex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.41</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000027/gale-20170403ex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Waiver dated April 1, 2017 to the Securities Purchase Agreement dated as of May 10, 2016 by and between the Registrant and JGB (Cayman) Newton Ltd.</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000027/gale-20170403ex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000027/gale-20170403ex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000027/gale-20170403ex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 3, 2017</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.42</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Voting Agreement by and between the Registrant and its named executive officers, Board of Directors and certain stockholders</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.2</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex102.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">March 12, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.43</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Warrant issued pursuant to that certain Securities Purchase Agreement dated March 7, 2018 by and between the Registrant and certain investors</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">March 12, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047819000011/sls-20190305x8xkex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.44</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047819000011/sls-20190305x8xkex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Warrant Exercise Agreement dated March 6, 2019</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047819000011/sls-20190305x8xkex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047819000011/sls-20190305x8xkex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047819000011/sls-20190305x8xkex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">March 6, 2019</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000031/gale-20170501xex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.45</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000031/gale-20170501xex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amendment Agreement dated May 1, 2017 between the Registrant and JGB (Cayman) Newton Ltd.</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000031/gale-20170501xex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000031/gale-20170501xex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000031/gale-20170501xex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">May 2, 2017</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000110465919057956/tm1921505d1_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.46</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000110465919057956/tm1921505d1_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Equity Distribution Agreement dated October 29, 2019, between the Registrant and Maxim Group LLC</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000110465919057956/tm1921505d1_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000110465919057956/tm1921505d1_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000110465919057956/tm1921505d1_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">October 31, 2019</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419034049/tv524889_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.47</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419034049/tv524889_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Investor Agreement</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419034049/tv524889_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419034049/tv524889_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000114420419034049/tv524889_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">July 9, 2019</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/sls20191231ex1048.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.48</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/sls20191231ex1048.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Stock Option Grant Notice and Option Agreement under the 2019 Equity Incentive Plan.</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/sls20191231ex1048.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/sls20191231ex1048.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.48</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/sls20191231ex1048.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">March 13, 2020</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/sls20191231ex1049.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.49</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/sls20191231ex1049.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Restricted Stock Unit Grant and Agreement under the 2019 Equity Incentive Plan.</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/sls20191231ex1049.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/sls20191231ex1049.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.49</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/sls20191231ex1049.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">March 13, 2020</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex141.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">14.1</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex141.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Code of Business Conduct and Ethics</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex141.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex141.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">14.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex141.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">January 5, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex211.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">21.1</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex211.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Subsidiaries of the Registrant</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex211.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10-K</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex211.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">21.1</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex211.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">April 13, 2018</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="tm2021170d1_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">23.1*</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="tm2021170d1_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Consent of Moss Adams LLP, Independent Registered Public Accounting Firm</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="tm2021170d1_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">23.2*</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="tm2021170d1_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1).</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt"><A HREF="#poa" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">24.1</FONT></A></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt"><A HREF="#poa" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Powers of Attorney (included on signature page hereto)</FONT></A></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">*</TD><TD STYLE="text-align: justify">Filed herewith.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">**</TD><TD STYLE="text-align: justify">Indicates management contract or compensatory plans or
arrangements.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">^</TD><TD STYLE="text-align: justify">The schedules and exhibits to this exhibit have been
omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC
upon request.</TD>
</TR></TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">+</TD><TD STYLE="text-align: justify">Confidential treatment has been granted with respect
to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: 0pt"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: 0pt">&nbsp;</P>

</BODY>
</HTML>
[{"type": "S-1", "sequence": "1", "filename": "tm2021170-1_s1.htm", "description": "FORM S-1", "secsgml_size_bytes": 386563}]
{"company-data": {"conformed-name": "SELLAS Life Sciences Group, Inc.", "cik": "0001390478", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-1", "act": "33", "file-number": "333-238799", "film-number": "20928414"}, "business-address": {"street1": "15 WEST 38TH STREET", "street2": "10TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10018", "phone": "(917) 438-4353"}, "mail-address": {"street1": "15 WEST 38TH STREET", "street2": "10TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10018"}, "former-company": [{"former-conformed-name": "Galena Biopharma, Inc.", "date-changed": "20110926"}, {"former-conformed-name": "RXi Pharmaceuticals Corp", "date-changed": "20110926"}, {"former-conformed-name": "GALENA BIOPHARMA, INC.", "date-changed": "20110922"}]}
As filed with the Securities and Exchange
Commission on May 29, 2020
Registration Statement No. 333-
[______]
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933
SELLAS
Life Sciences Group, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
2834
(Primary Standard Industrial
Classification Code Number)
15 West 38
th
St., 10
th
Floor
New York, NY 10018
(917) 438-4353
20-8099512
(I.R.S. Employer
Identification Number)
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)
Angelos M. Stergiou, M.D., Sc.D., h.c.
President and Chief Executive Officer
SELLAS Life Sciences Group, Inc.
15 West 38
th
St., 10
th
Floor
New York, NY 10018
(917) 438-4353
(Name, address, including zip code, and
telephone number, including area code, of agent for service)
Copies to:
Joel I. Papernik
Daniel A. Bagliebter
Mintz, Levin, Ferris, Cohn, Glovsky &
        Popeo, P.C.
666 Third Avenue
New York, NY 10017
Tel: (212) 935-3000
Barbara Wood
Executive Vice President, General
Counsel & Secretary
SELLAS Life Sciences Group, Inc.
15 West 38
th
St.,
10
th
Floor
New York, NY 10018
Tel: (917) 438-4353
Approximate date of commencement of proposed sale to public:
As soon as practicable after this Registration Statement is declared effective.
If any of the securities being registered on this Form are to
be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.
x
If this Form is filed to register additional securities for
an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.
¨
If this Form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering.
¨
If this Form is a post-effective amendment filed pursuant to
Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering.
¨
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or emerging growth company. See the definitions
of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging
growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated
    filer
¨
Accelerated
    filer
¨
Non-accelerated filer
x
Smaller reporting company
x
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 7(a)(2)(B) of the Securities Act.
☐
CALCULATION OF REGISTRATION FEE
Title of Each Class of
Securities to be Registered
Amount to be Registered (1)
Proposed
Maximum
Offering
Price per
Share
Proposed
Maximum
Aggregate
Offering Price
Amount of
Registration Fee (2)
Common Stock, $0.0001 par value per share, underlying the investor warrants
818,900
$
3.93
$
3,218,277
$
417.73
(1)
All of the shares of common stock offered hereby are for the account of selling stockholders and consist of 818,900 shares
issuable upon the exercise of warrants (the "Warrants"). Pursuant to Rule 416 of the Securities Act of 1933, as amended
(the "Securities Act"), this registration statement also covers any additional shares of common stock which become
issuable by reason of any share dividend, share split, recapitalization or any other similar transaction without receipt of consideration
which results in an increase in the number of shares of common stock outstanding.
(2)
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act based
upon the higher of (i) the price at which the warrants may be exercised, and (ii) $3.67, the average of the high and low prices
for a share of the registrant's common stock as reported on The Nasdaq Capital Market on May 27, 2020, which date is a date
within five business days of the filing of this registration statement.
The registrant hereby amends this Registration Statement
on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Commission, acting pursuant
to said Section 8(a), may determine.
The information contained in this preliminary
prospectus is not complete and may be changed. The selling stockholders identified in this prospectus may not sell these securities
until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is
not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer
or sale is not permitted.
SUBJECT TO COMPLETION,
DATED MAY 29, 2020
PRELIMINARY PROSPECTUS
818,900 Shares of Common Stock
This prospectus relates to the resale of
up to 818,900 shares of our common stock issuable upon exercise of certain outstanding warrants issued by us in a private placement.
We are not selling any shares of common
stock and will not receive any proceeds from the sale of the warrant shares by the selling stockholders under this prospectus.
Upon the exercise of the warrants for all 818,900 shares of our common stock by payment of cash, however, we will receive aggregate
gross proceeds of approximately $3.2 million.
These shares will be resold from time to
time by the entities listed in the section titled "Selling Stockholders" beginning on page 6, which we refer to
as the selling stockholders. The shares of common stock offered under this prospectus by the selling stockholders are issuable
upon exercise of warrants issued in a private placement pursuant to the Securities Purchase Agreement entered into by and among
SELLAS Life Sciences Group, Inc. and the selling stockholders, dated as of January 9, 2020 (the "Purchase Agreement").
We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of securities by
the selling stockholders.
The selling stockholders may sell the shares
of common stock described in this prospectus in a number of different ways and at varying prices. We provide more information about
how a selling stockholder may sell its shares of common stock in the section titled "Plan of Distribution" on page
8. We will pay the expenses incurred in registering the securities covered by the prospectus, including legal and accounting
fees.
Our common stock is traded on The Nasdaq
Capital Market under the symbol "SLS". On May 27, 2020, the last reported sale price of our common stock was $3.60
per share.
Investing in our common stock involves a high degree of risk.
See "Risk Factors" beginning on page 5 of this prospectus.
Neither the Securities and Exchange Commission, or the SEC,
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is May [___],
2020.
TABLE OF CONTENTS
PROSPECTUS SUMMARY
1
THE OFFERING
4
RISK FACTORS
5
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
5
USE OF PROCEEDS
6
SELLING STOCKHOLDERS
6
PLAN OF DISTRIBUTION
8
DESCRIPTION OF CAPITAL STOCK
10
LEGAL MATTERS
14
EXPERTS
14
WHERE YOU CAN FIND MORE INFORMATION
14
INCORPORATION OF DOCUMENTS BY REFERENCE
14
You should rely only on the information we have included or
incorporated by reference into this prospectus. We have not authorized anyone to provide you with any representation other than
those contained or incorporated by reference into this prospectus. You must not rely upon any information or representation not
contained or incorporated by reference into this prospectus. This prospectus does not constitute an offer to sell or the solicitation
of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such
jurisdiction. You should not assume the information contained in this prospectus is accurate on any date subsequent to the date
set forth on the front of the document or that any information we have incorporated by reference herein is correct on any date
subsequent to the date of the document incorporated by reference, even though this prospectus is delivered, or securities are sold,
on a later date.
"SELLAS Life Sciences Group, Inc.," "SELLAS,"
the SELLAS logo, and other trademarks or service marks of SELLAS appearing in this prospectus are the property of our company.
Other third-party logos and product/trade names are registered trademarks or trade names of their respective companies. Solely
for convenience, trademarks and tradenames referred to in this prospectus appear (after the first usage) without the ® and
 ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent
under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames.
This prospectus contains or incorporates by reference summaries
of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete
information. All the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred
to herein have been filed or have been incorporated by reference as exhibits to the registration statement of which this prospectus
forms a part, and you may obtain copies of those documents as described in this prospectus under the heading "
Where You
Can Find More Information
."
Smaller Reporting Company – Scaled
Disclosure
Pursuant to Item 10(f) of Regulation S-K promulgated under the
Securities Act of 1933, as indicated herein, we have elected to comply with the scaled disclosure requirements applicable to "smaller
reporting companies," including providing two years of audited financial statements.
i
PROSPECTUS SUMMARY
This summary highlights information contained in other parts
of this prospectus. Because it is only a summary, it does not contain all the information you should consider before investing
in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information
appearing elsewhere in this prospectus and the information incorporated by reference herein. You should read all such documents
carefully, especially the risk factors and our audited consolidated financial statements and the related notes included herein,
before deciding to buy our securities. Unless the context requires otherwise, references in this prospectus to "SELLAS,"
 "Company," "we," "us" and "our" refer to SELLAS Life Sciences Group, Inc. and our
subsidiaries.
Company Overview
We are a late-stage clinical biopharmaceutical company focused
on developing novel cancer immunotherapeutics for a broad range of cancer indications. Our product candidates currently include
galinpepimut-S and nelipepimut-S.
Pipeline
Galinpepimut-S, or GPS
Our lead product candidate, galinpepimut-S, or GPS, is a cancer
immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein,
which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has potential
as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers
and solid tumor indications.
In January 2020, we commenced a Phase 3 trial for GPS monotherapy
in patients with acute myeloid leukemia, or AML, in the maintenance setting after achievement of their second complete remission,
or CRem2, following successful completion of second-line antileukemic therapy, which we refer to as the REGAL study. We expect
this study will be used as the basis for a Biologics License Application, or BLA, submission, subject to a statistically significant
and clinically meaningful data outcome and agreement with the U.S. Food & Drug Administration, or the FDA. The study is expected
to enroll approximately 116 patients at approximately 50 clinical sites in the United States and Europe and is contemplated to
have a planned interim safety and futility analysis after 80 events (deaths).
In December 2018, we initiated a Phase 1/2 multi-arm ("basket"
type) clinical study of GPS in combination with Merck & Co., Inc.'s anti-PD-1 therapy, Keytruda® (pembrolizumab).
We plan to enroll up to approximately 90 patients at up to 20 centers in the United States. The initial tumor types being studied
are ovarian cancer (second or third line) and colorectal cancer (third or fourth line) with up to approximately 40 patients in
total in these two indications, to be followed by AML (in patients having achieved partial response as their best hematological
response after four cycles of therapy with hypomethylating agents), triple negative breast cancer, or TNBC, (second line), and
small cell lung cancer, or SCLC.
GPS was granted Orphan Drug Product Designations from the FDA,
as well as Orphan Medicinal Product Designations from the European Medicines Agency, or EMA, for GPS in AML, malignant pleural
mesothelioma, or MPM, and multiple myeloma, or MM, as well as Fast Track Designation for AML, MPM, and MM from the FDA.
Nelipepimut-S or NPS
Nelipepimut-S, or NPS, is a cancer immunotherapy targeting the
human epidermal growth factor receptor 2, or HER2, expressing cancers. Data presented in 2018 from a Phase 2b clinical trial of
the combination of trastuzumab (Herceptin®) plus NPS in HER2 low expressing (1+ or 2+ per immunohistochemistry, or IHC) breast
cancer patients in the adjuvant setting to prevent recurrences showed a clinically and statistically significant improvement in
the disease-free survival, or DFS, rate for the TNBC cohort at 24 months for patients treated with NPS plus trastuzumab of 92.6%
compared to 70.2% for those treated with trastuzumab alone. Following ongoing discussions with the FDA and based upon written feedback
from the FDA and on the totality of clinical, safety and translational NPS data to date, we have finalized the design and plan
for a Phase 3 registration-enabling study of NPS in combination with trastuzumab for the treatment of patients with TNBC in the
adjuvant setting after standard treatment. If successful, we believe this study may be considered as the basis for a BLA submission
to the FDA. We are seeking out-licensing opportunities to fund and conduct the future clinical development of NPS in order to maximize
the potential of the program and we do not plan to conduct and fund a Phase 3 program for NPS on our own.
FBP-targeting bivalent vaccine (GALE-301/-302)
In order to prioritize development of our core assets, we have
determined to cease development of GALE-301 and GALE-302, cancer immunotherapies that target the E39 peptide derived from the folate
binding protein, or FBP, which were licensed in from The Henry M. Jackson Foundation, or HJF, and the MD Anderson Cancer Center,
or MDACC. We are currently negotiating a termination of the license agreement with HJF and MDACC.
The chart below summarizes the current status of our clinical
development pipeline:
Cancer Immunotherapy Market Overview
According to a January 2020 report by Kelly Scientific Publications,
cancer immunotherapy drugs have already captured nearly 50% of the overall oncology drugs market in 2019, generating about $75
billion in that year alone, and are forecast to surpass $115 billion in 2023. Additionally, an October 2019 Allied Market Research
report on the estimated entire market value of oncology drugs (of any type) suggests that cancer immunotherapies could represent
up to 77% of that total value by 2023. According to a report published in September 2018, it was projected that approximately 70%
of the 2019 immunotherapy market would be comprised of checkpoint inhibitors (~30% of the market share), immune synapse co-stimulators
and bispecific monoclonal antibodies (~40% of the market share), as well as approximately 30% of other immunotherapies, including
chimeric antigen receptor (CAR) T-cell therapies and other cell-based modalities (e.g., ex vivo modified natural killer or NK cells).
It is predicted that the checkpoint inhibitor market share will decrease slightly by 2023, reaching a 27% value (from a 30% value
in 2019), as novel therapies, including peptide cancer active immunizers (vaccines) such as our product candidates, GPS and NPS
and cell-based therapies, advance into regulatory approvals and use in the cancer market.
The total number of newly diagnosed patients with AML per year
in the United States is approximately 21,450 (2019 epidemiological data: American Cancer Society). It is estimated that the number
of adult patients of any age with AML in the United States per year who successfully enter into CRem2, the indication of our REGAL
study, is approximately 2,000 patients and approximately 4,700 patients outside of the United States in the rest of the world,
or ROW, while the number of patients who achieve CRem1 is estimated to be approximately 16,400 patients in the United States and
approximately 38,100 patients ROW. The number of patients potentially eligible for GPS maintenance therapy after achievement of
CRem2 status is approximately 1,200 patients in the United States and approximately 2,800 patients ROW.
Recent Developments
On March 11, 2020, the World Health Organization declared the
outbreak of a new coronavirus to be a "pandemic." First identified in 2019 and known now as COVID-19, the outbreak
has resulted in various "stay-at-home" and "shutdown" orders through the various states in the United States
as well as most countries worldwide. The pandemic has impacted millions of individuals and businesses worldwide. As we have functioned
operationally as a semi-virtual company, the transition to "work-from home" for our employees has not materially altered
our business operations. Our Phase 3 REGAL study is in its early stages, with the necessary work to activate additional sites in
the United States and Europe continuing without material interruption. Screening is ongoing at the majority of the sites in the
GPS + pembrolizumab combination study although certain sites have limited operations to some extent. Due to the uncertainty of
these limitations regarding the sites, we now expect initial clinical data in the first half of 2021. We have been informed by
MSK that while it is continuing to dose the patients already enrolled in the MPM IST, it is not currently enrolling additional
patients. We believe that the COVID-19 pandemic has not materially impacted our efforts to out-license NPS. The extent to which
the coronavirus impacts the Company's operations will depend on future developments, which are highly uncertain and cannot be predicted
with confidence, including the duration of the outbreak, the re-emergence of a second outbreak in the fall or winter, new information
which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among
others. In particular, the continued spread of the coronavirus globally could adversely impact the Company's clinical trial operations
and could have an adverse impact on the Company's business and the Company's financial results.
2
Risks Associated with Our Business
Our business is subject to a number of risks of which you should
be aware before making an investment decision. These risks are discussed more fully in the "
Risk Factors
" section
of this prospectus immediately following this prospectus summary. These risks include the following:
·
Our business may be adversely affected by the recent coronavirus outbreak.
·
We have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing
losses for the foreseeable future.
·
We will need significant additional financing to fund our operations and complete the development and, if approved, the commercialization
of our product candidates. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our
product development programs or commercialization efforts.
·
We currently have no source of revenues. We may never generate revenues or achieve profitability.
·
We expect to continue to incur significant operating and non-operating expenses, which may make it difficult for us to secure
sufficient financing and may lead to uncertainty about our ability to continue as a going concern.
·
We have announced that we are considering strategic alternatives in order to maximize stockholder value. We may not be able
to identify or consummate a suitable transaction as a result of this review.
·
We have been involved in multiple legal and governmental proceedings, and may in the future be involved in proceedings, relating
to the commercial activities of our predecessor that could adversely affect our financial condition and our business.
·
We are dependent on technologies we license, and if we lose the right to license such technologies or we fail to license new
technologies in the future, our ability to develop new products would be harmed, and if we fail to meet our obligations under our
license agreements, we may lose the ability to develop our product candidates.
·
We are currently a clinical-stage biopharmaceutical company with product candidates in clinical development. If we are unable
to successfully develop and commercialize product candidates or experiences significant delays in doing so, our business may be
materially harmed.
·
Our future success is dependent on the regulatory approval of our product candidates.
Additional Information
For additional information related to our business and operations,
please refer to the reports incorporated herein by reference, including our
Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the SEC on March 13, 2020
, or the 2019 Form 10-K, our
Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 as filed with the SEC on May 14, 2020
, or the 2020 Form 10-Q, and our Current Reports on Form 8-K as filed
with the SEC, as described in the section entitled "
Incorporation of Documents by Reference
" beginning on page
14 of this prospectus.
Our Corporate Information
We were incorporated on April 3, 2006 in Delaware as Argonaut
Pharmaceuticals, Inc. On November 28, 2006, we changed our name to RXi Pharmaceuticals Corporation and began operations in January
2007. On September 26, 2011, we changed our name to Galena Biopharma, Inc. In December, 2017, we completed the business combination
with the privately held Bermuda exempted company, Sellas Life Sciences Group Ltd., or Private SELLAS, which we refer to throughout
the registration statement of which this prospectus forms a part as the "Merger." As a result of the Merger, our business
is now substantially comprised of the business of Private SELLAS. Upon completion of the Merger, we changed our name from "Galena
Biopharma, Inc." to "SELLAS Life Sciences Group, Inc.," our common stock began trading on The Nasdaq Capital
Market under a new ticker symbol "SLS" on January 2, 2018 and our financial statements became those of Private SELLAS.
Our principal executive offices are located at 15 West 38
th
Street, 10
th
Floor, New York, NY 10018, and our phone number is (917) 438-4353. Our website address is www.sellaslife.com.
The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our
website address in this prospectus solely as an inactive textual reference.
Registered Direct Offering of Common Stock and Concurrent
Private Placement of Warrants
On January 9, 2020, we entered into a Securities Purchase Agreement
(the "Purchase Agreement") with certain investors named therein (the "Investors"), pursuant to which we
agreed to issue and sell, in a registered direct offering directly to the Investors (the "Registered Offering"), (i)
an aggregate of 1,189,000 shares (the "Shares") of our common stock at an offering price of $3.9825 per share and (ii)
an aggregate of 448,800 pre-funded warrants exercisable for shares of common stock (the "Pre-Funded Warrants") at an
offering price of $3.9725 per Pre-Funded Warrant, for gross proceeds of approximately $6.5 million before deducting the placement
agent fee and related offering expenses.
In a concurrent private placement (the "Private Placement"
and together with the Registered Offering, the "Offerings"), we agreed to issue to the Investors who participated in
the Registered Offering warrants (the "Warrants" and collectively with the Shares and the Pre-Funded Warrants, the
 "Securities") exercisable for an aggregate of 818,900 shares of common stock at an exercise price of $3.93 per share.
Each Warrant was immediately exercisable and will expire five and one-half years from the issuance date. The Warrants and the shares
of our common stock issuable upon the exercise of the Warrants were offered pursuant to the exemption provided in Section 4(a)(2)
under the Securities Act and Rule 506(b) promulgated thereunder. We closed such Offerings on January 13, 2020.
3
THE OFFERING
Securities offered by the selling stockholders
818,900 shares.
Common Stock to be outstanding after this offering, assuming exercise of the Warrants issued pursuant to the Purchase Agreement
7,536,800 shares.
Terms of the offering
The selling stockholders and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their shares covered hereby on The Nasdaq Capital Market or any other stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. See "Plan of Distribution."
Use of Proceeds
We may receive up to approximately $3.2 million in aggregate gross proceeds from cash exercises of the Warrants, based on the per share exercise price of the Warrants. Any proceeds we receive from the exercise of the Warrants will be used to advance our clinical programs and for general corporate purposes. See "Use of Proceeds."
Risk Factors
An investment in our securities involves a high degree of risk. See the section entitled "
Risk Factors
" beginning on page 5 of this prospectus and the similarly entitled sections in the documents incorporated by reference into this prospectus.
Nasdaq Capital Market symbol
Our common stock is quoted on The Nasdaq Capital Market under the symbol "SLS."
Except as otherwise indicated herein, the number of shares of
our common stock to be outstanding after this offering is based on 6,717,900 shares of common stock outstanding as of March 31,
2020 and excludes:
·
1,210,148 shares of Common Stock issuable as of the date hereof upon the exercise of common stock warrants outstanding as of
March 31, 2020 at a weighted average exercise price of $34.01 per share;
·
193,520 shares of Common Stock issuable upon the exercise of stock options outstanding as of March 31, 2020 at a weighted-average
exercise price of $14.23 per share;
·
170,000 shares of Common Stock issuable upon the vesting of restricted stock units outstanding as of March 31, 2020 at a weighted-average
grant date fair value of $1.89 per share;
·
114,689 shares of Common Stock available for future issuance under the 2019 Equity Incentive Plan as of March 31, 2020; and
·
8,302 shares of Common Stock available for future issuance under the Employee Stock Purchase Plan as of March 31, 2020.
4
RISK FACTORS
Investing in our securities involves a high degree of risk.
Before investing in our securities, you should carefully consider the risks, uncertainties and assumptions contained in this prospectus
and discussed under the heading "Risk Factors" included in our most recent
Annual Report on Form 10-K for the year ended December 31, 2019
, as revised or supplemented by subsequent filings, which are on file with the SEC and are incorporated
herein by reference, and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC
in the future. Our business, financial condition, results of operations and future growth prospects could be materially and adversely
affected by any of these risks. In these circumstances, the market price of our common stock could decline, and you may lose all
or part of your investment.
SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS
This prospectus and the documents incorporated by reference
into this prospectus include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended, that relate to future events or our future financial performance and involve
known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or
achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied
by these forward-looking statements. Words such as, but not limited to, "anticipate," "aim," "believe,"
 "contemplate," "continue," "could," "design," "estimate," "expect,"
 "intend," "may," "might," "plan," "predict," "poise," "project,"
 "potential," "suggest," "should," "strategy," "target," "will,"
 "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify
forward-looking statements, although not all forward-looking statements contain these identifying words. Although we believe that
we have a reasonable basis for each forward-looking statement contained in this prospectus and incorporated by reference into this
prospectus, we caution you that these statements are based on our projections of the future that are subject to known and unknown
risks and uncertainties and other factors that may cause our actual results, level of activity, performance or achievements expressed
or implied by these forward-looking statements, to differ. The section in this prospectus entitled "
Risk Factors
"
and the sections in our periodic reports, including the 2019 Form 10-K entitled "Business," and in the 2019 Form 10-K
and the 2020 Form 10-Q entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations,"
as well as other sections in this prospectus and the documents or reports incorporated by reference into this prospectus, discuss
some of the factors that could contribute to these differences. These forward-looking statements include, among other things, statements
about:
·
the extent to which our business may be adversely affected by the recent COVID-19 outbreak;
·
our projected financial position and estimated cash burn rate;
·
our estimates regarding expenses, future revenues and capital requirements;
·
our ability to continue as a going concern;
·
our need to raise substantial additional capital to fund our operations;
·
the success, cost and timing of our clinical trials;
·
our dependence on third parties in the conduct of our clinical trials;
·
our ability to obtain the necessary regulatory approvals to market and commercialize our product candidates;
·
the potential that results of preclinical and clinical trials indicate our current product candidates or any future product
candidates we may seek to develop are unsafe or ineffective;
·
the results of market research conducted by us or others;
·
our ability to obtain and maintain intellectual property protection for our current product candidates;
·
our ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to
enforce or protect our intellectual property rights;
·
the possibility that a third party may claim we have infringed, misappropriated or otherwise violated their intellectual property
rights and that we may incur substantial costs and be required to devote substantial time defending against these claims;
·
our reliance on third-party suppliers and manufacturers;
·
the success of competing therapies and products that are or become available;
·
our ability to expand our organization to accommodate potential growth and our ability to retain and attract key personnel;
·
the potential for us to incur substantial costs resulting from product liability lawsuits against us and the potential for
these product liability lawsuits to cause us to limit our commercialization of our product candidates;
·
market acceptance of our product candidates, the size and growth of the potential markets for our current product candidates
and any future product candidates we may seek to develop, and our ability to serve those markets; and
·
the successful development of our commercialization capabilities, including sales and marketing capabilities.
5
Our current product candidates are undergoing clinical development
and have not been approved by the FDA or the European Commission. These product candidates have not been, nor may they ever be,
approved by any regulatory agency or competent authorities nor marketed anywhere in the world.
We may not actually achieve the plans, intentions or
expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking
statements. Forward-looking statements should be regarded solely as our current plans, estimates and beliefs. We have
included important factors in the cautionary statements included in this document, particularly in the section entitled
 "
Risk Factors
" beginning on page 5 of this prospectus that we believe could cause actual results or events
to differ materially from the forward-looking statements that we make. Moreover, we operate in a very competitive and rapidly
changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can
we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any forward-looking statements we may make. Given these risks and
uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary statement. Our forward-looking statements do not reflect the
potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. You should
read this prospectus and the documents that we have filed as exhibits to this prospectus and incorporated by reference herein
completely and with the understanding that our actual future results may be materially different from the plans, intentions
and expectations disclosed in the forward-looking statements we make. The forward-looking statements contained in this
prospectus are made as of the date of this prospectus and we do not assume any obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
USE OF PROCEEDS
We will not receive any of the proceeds from the sale of securities
by the selling stockholders pursuant to this prospectus. We may receive up to approximately $3.2 million in aggregate gross proceeds
from cash exercises of the Warrants, based on the per share exercise price of the Warrants. Any proceeds we receive from the exercise
of the Warrants will be used to advance our clinical programs and for general corporate purposes.
SELLING STOCKHOLDERS
The shares of common stock being offered
by the selling stockholders are those issuable upon the exercise of the Warrants. For additional information regarding the issuance
of these securities, see "Prospectus Summary—Registered Direct Offering of Common Stock and Concurrent Private Placement
of Warrants" on page 3 of this prospectus. We are registering the shares of common stock issuable upon exercise of the
Warrants in order to permit the selling stockholders to offer the shares for resale from time to time. Except for the ownership
of the Warrants, the transactions contemplated pursuant to the Purchase Agreement and other financings completed by us, the selling
stockholders have not had any material relationship with us within the past three years.
The following table sets forth certain
information with respect to each selling stockholder, including (i) the shares of our common stock beneficially owned by the selling
stockholder prior to this offering, (ii) the number of shares being offered by the selling stockholder pursuant to this prospectus
and (iii) the selling stockholder's beneficial ownership after completion of this offering. The registration of the shares
of common stock issuable to the selling stockholders upon the exercise of the Warrants does not necessarily mean that the selling
stockholders will sell all or any of such shares, but the number of shares and percentages set forth in the final two columns below
assume that all shares of common stock being offered by the selling stockholders are sold.
The table is based on information supplied
to us by the selling stockholders, with beneficial ownership and percentage ownership determined in accordance with the rules and
regulations of the SEC, and includes voting or investment power with respect to shares of stock. This information does not necessarily
indicate beneficial ownership for any other purpose. In computing the number of shares beneficially owned by a selling stockholder
and the percentage ownership of that selling stockholder, shares of common stock subject to warrants held by that selling stockholder
that are exercisable within 60 days after May 29, 2020, are deemed outstanding. Such shares, however, are not deemed outstanding
for the purposes of computing the percentage ownership of any other person. The percentage of beneficial ownership after this offering
is based on 6,717,900 shares of common stock outstanding on May 14, 2020.
This prospectus covers the resale of 818,900
shares of our common stock that may be sold or otherwise disposed of by the selling stockholders. Such shares are issuable to the
selling stockholders upon the exercise of the Warrants. The Warrants are immediately exercisable on the date of their issuance
and expire five and a half (5.5) years from the date they became exercisable. All of the Warrants have an exercise price of $3.93
per share. See "Prospectus Summary —Registered Direct Offering of Common Stock and Concurrent Private Placement of
Warrants" above for a complete description of the Warrants. The selling stockholders may sell all, some or none of their
shares in this offering, but the number of shares and percentages set forth in the final two columns below assume that all shares
of common stock being offered by the selling stockholders are sold. See "Plan of Distribution."
6
Selling
Security Holder (1)
Number of Shares
of
Common Stock
Beneficially
Owned
Prior to Offering (2)
Number of Shares
of
Common Stock
Underlying Warrants Offered
Hereby (3)
Number of Shares
of
Common Stock
Beneficially Owned
After Offering (4)
% of Shares
of Common
Stock Beneficially Owned
After
Offering (4)
Anson Investments Master Fund LP (5)
409,900
409,900
0
*
CVI Investments, Inc. (5)
415,323
409,000
6,323
*
*
Less than one percent.
(1)
This table and the information in the notes below are based upon information supplied by the selling stockholder, including
reports and amendments thereto filed with the SEC on Schedule 13D and Schedule 13G.
(2)
The shares of common stock underlying warrants are convertible or exercisable within 60 days of May 29, 2020.
(3)
The actual number of shares of common stock offered hereby and included in the registration statement of which this prospectus
forms a part includes, in accordance with Rule 416 under the Securities Act, such indeterminate number of additional shares of
our common stock as may become issuable in connection with any proportionate adjustment for any stock splits, stock combinations,
stock dividends, recapitalizations or similar events with respect to the common stock.
(4)
Assumes the exercise in full of the warrants and sale of all warrant shares registered pursuant to this prospectus, although
the selling stockholders are under no obligation known to us to sell any shares of common stock at this time.
(5)
Anson Advisors Inc and Anson Funds Management LP,
the Co-Investment Advisers of Anson Investments Master Fund LP ("Anson"), hold voting and dispositive power over the
Common Shares held by Anson. Bruce Winson is the managing member of Anson Management GP LLC, which is the general partner of Anson
Funds Management LP. Moez Kassam and Amin Nathoo are directors of Anson Advisors Inc. Mr. Winson, Mr. Kassam and Mr. Nathoo each
disclaim beneficial ownership of these Common Shares except to the extent of their pecuniary interest therein. The principal business
address of Anson is Walkers Corporate Limited, Cayman Corporate Centre, 27 Hospital Road, George Town, Grand Cayman KY1-9008,
Cayman Islands.
(6)
Heights Capital Management, Inc., the authorized agent
of CVI Investments, Inc. ("CVI"), has discretionary authority to vote and dispose of the shares held by CVI and may
be deemed to be the beneficial owner of these shares. Martin Kobinger, in his capacity as Investment Manager of Heights Capital
Management, Inc., may also be deemed to have investment discretion and voting power over the shares held by CVI.  Mr. Kobinger
disclaims any such beneficial ownership of the shares.  CVI Investments, Inc. is affiliated with one or more FINRA member,
none of whom are currently expected to participate in the sale pursuant to the prospectus contained in the Registration Statement
of Shares purchased by the Investor in this Offering.  The principal business address of Heights is PO Box 309GT, Ugland
House, South Church Street, George Town, Grand Cayman, Cayman Islands.
7
PLAN OF DISTRIBUTION
Each selling stockholder of the securities
and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered
hereby on The Nasdaq Capital Market or any other stock exchange, market or trading facility on which the securities are traded
or in private transactions. These sales may be at fixed or negotiated prices. A selling stockholder may use any one or more of
the following methods when selling securities:
·
ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
·
block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion
of the block as principal to facilitate the transaction;
·
purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
·
an exchange distribution in accordance with the rules of the applicable exchange;
·
privately negotiated transactions;
·
settlement of short sales;
·
in transactions through broker-dealers that agree with the selling stockholders to sell a specified number of such securities
at a stipulated price per security;
·
through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
·
a combination of any such methods of sale; or
·
any other method permitted pursuant to applicable law.
The selling stockholders may also sell
securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this
prospectus.
Broker-dealers engaged by the selling stockholders
may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling
stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated,
but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary
brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction, a markup or markdown in compliance
with FINRA IM-2440.
In connection with the sale of the securities
or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions,
which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The selling stockholders
may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities
to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions
with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such
broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other
financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
The selling stockholders and any broker-dealers
or agents that are involved in selling the securities may be deemed to be "underwriters" within the meaning of the
Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any
profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities
Act. Each selling stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly
or indirectly, with any person to distribute the securities.
The Company is required to pay certain
fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the
selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.
We agreed to keep this prospectus effective
until the earlier of (i) the date on which the securities may be resold by the selling stockholders without registration and without
regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance
with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of
the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect.
The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities
laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or
qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and
is complied with.
8
Pursuant to applicable rules and
regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously
engage in market making activities with respect to the common stock for the applicable restricted period, as defined in
Regulation M, prior to the commencement of the distribution. In addition, the selling stockholders will be subject to
applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit
the timing of purchases and sales of the common stock by the selling stockholders or any other person. We will make copies of
this prospectus available to the selling stockholders and have informed them of the need to deliver a copy of this prospectus
to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).
9
DESCRIPTION OF CAPITAL STOCK
The following description of our capital stock summarizes the
material terms and provisions of our common stock and our preferred stock. For the complete terms of our common stock, please refer
to our amended and restated certificate of incorporation and our amended and restated bylaws, each as amended to date, that are
incorporated by reference into the registration statement of which this prospectus is a part or may be incorporated by reference
into this prospectus. The terms of these securities may also be affected by the Delaware General Corporation Law, or the DGCL.
The summary below is qualified in its entirety by reference to our amended and restated certificate of incorporation and amended
and restated bylaws, each as in effect at the time of any offering of securities under this prospectus.
General
Our amended and restated
certificate of incorporation authorizes us to issue up to 350,000,000 shares of common stock, $0.0001 par value per share, and
5,000,000 shares of preferred stock, $0.0001 par value per share
.
As of March 31, 2020, there were:
·
6,717,900 shares of common stock outstanding;
·
193,520 shares of common stock issuable upon exercise of outstanding options;
·
170,000 shares of common stock issuable upon settlement of outstanding RSUs; and
·
warrants outstanding for the purchase of an aggregate of 1,120,148 shares of common stock;
Common Stock
Voting
Each holder of our common
stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of
directors. Our amended and restated certificate of incorporation and amended and restated bylaws do not provide for cumulative
voting rights. Because of this absence of cumulative voting, the holders of a majority of the shares of common stock entitled to
vote in any election of directors can elect all the directors standing for election, if they should so choose
.
Dividends
Subject to preferences
that may be applicable to any then outstanding shares of preferred stock, holders of common stock are entitled to receive ratably
those dividends, if any, as may be declared from time to time by our board of directors out of legally available funds
.
Liquidation
In the event of our dissolution
or liquidation, holders of common stock will be entitled to share ratably in the net assets legally available for distribution
to stockholders after the payment of all our debts and other liabilities and the satisfaction of any preferential rights that may
be granted to the holders of any then outstanding shares of preferred stock
.
Rights and Preferences
Holders of common stock
have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to the
common stock. The rights, preferences, and privileges of the holders of common stock are subject to, and may be adversely affected
by, the rights of the holders of shares of any series of preferred stock
.
Fully-paid
All of the outstanding
shares of our common stock are, and the shares of common stock issued upon the conversion of any securities convertible into our
common stock will be, fully paid and non-assessable. The shares of common stock offered by this prospectus or upon the
conversion of any preferred stock or debt securities or exercise of any warrants offered pursuant to this prospectus, when issued
and paid for, will also be, fully paid and non-assessable
.
Preferred Stock
Under our amended and restated certificate
of incorporation, our board of directors has the authority, without further action by our stockholders, to issue up to 5,000,000
shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These
rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation
preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all
of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting
power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation.
In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change of control of
our company or other corporate action.
10
The following summary of terms of our
preferred stock is not complete. You should refer to the provisions of our amended and restated certificate of incorporation and
amended and restated bylaws and the resolutions containing the terms of each class or series of the preferred stock which have
been or will be filed with the SEC at or prior to the time of issuance of such class or series of preferred stock and described
in the applicable prospectus supplement. The applicable prospectus supplement may also state that any of the terms set forth herein
are inapplicable to such series of preferred stock, provided that the information set forth in such prospectus supplement does
not constitute material changes to the information herein such that it alters the nature of the offering or the securities offered.
Our board of directors will fix the
designations, voting powers, preferences and rights of the preferred stock of each series we issue under this prospectus, as well
as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will
file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports
that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock
we are offering. We will describe in the applicable prospectus supplement the terms of the series of preferred stock being offered,
including, to the extent applicable:
·
the title and stated value;
·
the number of shares we are offering;
·
the liquidation preference per share;
·
the purchase price;
·
the dividend rate, period and payment date and method of calculation for dividends;
·
whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;
·
the procedures for any auction and remarketing;
·
the provisions for a sinking fund;
·
the provisions for redemption or repurchase and any restrictions on our ability to exercise those redemption and repurchase
rights;
·
any listing of the preferred stock on any securities exchange or market;
·
whether the preferred stock will be convertible into our common stock or other securities, and the conversion rate or conversion
price, or how they will be calculated, and the conversion period;
·
whether the preferred stock will be exchangeable into debt securities, and the exchange rate or exchange price, or how they
will be calculated, and the exchange period;
·
voting rights of the preferred stock;
·
preemptive rights;
·
restrictions on transfer, sale or other assignment;
·
whether interests in the preferred stock will be represented by depositary shares;
·
a discussion of material or special U.S. federal income tax considerations applicable to the preferred stock;
·
the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind
up our affairs;
·
any limitations on the issuance of any class or series of preferred stock ranking senior to or on parity with the series of
preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and
·
any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock.
11
If we issue shares of preferred stock under this prospectus,
they will be validly issued, fully paid and non-assessable.
The DGCL provides that the holders of preferred stock will have
the right to vote separately as a class on any proposal involving fundamental changes in the rights of holders of such preferred
stock. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation.
The issuance of our preferred stock could adversely affect the
voting power, conversion or other rights of holders of common stock and reduce the likelihood that such holders will receive dividend
payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring
or preventing a change in control of our company or other corporate action. Additionally, the issuance of preferred stock may have
the effect of decreasing the market price of our common stock.
Warrants
As
of March 31, 2020, we had warrants outstanding to purchase
1,120,148
shares
of our common stock.
Possible Anti-Takeover Effects of Delaware Law and Our Certificate
of Incorporation and Bylaws
Provisions of the DGCL and our amended
and restated certificate of incorporation and amended and restated bylaws could make it more difficult to acquire our company by
means of a tender offer, a proxy contest or otherwise, or to remove incumbent officers and directors. These provisions, summarized
below, are expected to discourage certain types of coercive takeover practices and takeover bids that our board of directors may
consider inadequate and to encourage persons seeking to acquire control of our company to first negotiate with our board of directors.
We believe that the benefits of increased protection of our ability to negotiate with the proponent of an unfriendly or unsolicited
proposal to acquire or restructure our company outweigh the disadvantages of discouraging takeover or acquisition proposals because,
among other things, negotiation of these proposals could result in an improvement of their terms.
Classified Board
Our amended and restated certificate
of incorporation and our amended and restated bylaws provide that our board of directors is divided into three classes. The directors
designated as Class I directors have terms expiring at the annual meeting of stockholders in 2020. The directors designated
as Class II directors will have terms expiring at the annual meeting of stockholders in 2021, and the directors designated
as Class III directors will have terms expiring at the annual meeting of stockholders in 2022. Directors for each class will
be elected at the annual meeting of stockholders held in the year in which the term for that class expires and thereafter will
serve for a term of three years. In order to more evenly divide the classes of directors, and consistent with our amended and
restated bylaws, John Varian has agreed that, if he is reelected at the 2020 annual meeting as a Class I director, he will resign
from his Class I director seat, and the Board will simultaneously appoint him to a newly created directorship in Class III. As
a result, Mr. Varian would be up for reelection with other Class III directors at the 2022 annual meeting, rather than with the
Class I directors at the 2023 annual meeting.
At any meeting of stockholders for the election of directors at which a quorum is present, the
election will be determined by a plurality of the votes cast by the stockholders entitled to vote at the election. Under the classified
board provisions, it would take at least two elections of directors for any individual or group to gain control of our board. Accordingly,
these provisions could discourage a third party from initiating a proxy contest, making a tender offer or otherwise attempting
to gain control of our company.
Removal of Directors
Our amended and restated bylaws provide
that our stockholders may only remove our directors with cause.
Amendment
Our amended and restated certificate
of incorporation and our amended and restated bylaws provide that the affirmative vote of the holders of at least 75% of our voting
stock then outstanding is required to amend certain provisions relating to the number, term, election and removal of our directors,
the filling of our board vacancies, stockholder notice procedures, the calling of special meetings of stockholders and the indemnification
of directors. Further, any amendments of our bylaws must be approved by our stockholders as our amended and restated certificate
of incorporation does not authorize our board of directors to amend our bylaws.
Size of Board and Vacancies
Our amended and restated bylaws provide
that the number of directors on our board of directors is fixed exclusively by our board of directors. Newly created directorships
resulting from any increase in our authorized number of directors will be filled by a majority of our board of directors then in
office, provided that a majority of the entire board of directors, or a quorum, is present and any vacancies in our board of directors
resulting from death, resignation, retirement, disqualification, removal from office or other cause will be filled generally by
the majority vote of our remaining directors in office, even if less than a quorum is present.
12
Special Stockholder Meetings
Our amended and restated certificate
of incorporation provides that only the Chairman of our board of directors, our Chief Executive Officer or our board of directors
pursuant to a resolution adopted by a majority of the total number of directors we would have if there were no vacancies may call
special meetings of our stockholders.
Stockholder Action by Unanimous Written Consent
Our amended and restated certificate
of incorporation expressly eliminates the right of our stockholders to act by written consent.
Requirements for Advance Notification
of Stockholder Nominations and Proposals
Our amended and restated bylaws provide
advance notice procedures with respect to stockholder proposals and nomination of candidates for election as directors other than
nominations made by or at the direction of board of directors or a committee of our board of directors.
No Cumulative Voting
The DGCL provides that stockholders
are denied the right to cumulate votes in the election of directors unless our certificate of incorporation provides otherwise.
Our amended and restated certificate of incorporation does not provide for cumulative voting.
Undesignated Preferred Stock
The authority that is possessed by
our board of directors to issue preferred stock could potentially be used to discourage attempts by third parties to obtain control
of our company through a merger, tender offer, proxy contest, or otherwise by making it more difficult or costlier to obtain control
of our company. Our board of directors may issue preferred stock with voting rights or conversion rights that, if exercised, could
adversely affect the voting power of the holders of common stock.
Authorized but Unissued Shares
Our authorized but unissued shares
of common stock and preferred stock will be available for future issuance without stockholder approval. We may use additional shares
for a variety of purposes, including future public offerings to raise additional capital, to fund acquisitions and as employee
compensation. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or
discourage an attempt to obtain control of our company by means of a proxy contest, tender offer, merger or otherwise.
The above provisions may deter a hostile
takeover or delay a change in control or management of our company.
Listing on The Nasdaq Capital Market
Our common stock is listed on The Nasdaq
Capital Market under the symbol "SLS". On May 27, 2020, the closing price of our common stock was $3.60 per share.
As of May 27, 2020, we had approximately 26 stockholders of record.
The applicable prospectus supplement
will contain information, where applicable, as to other listing, if any, on The Nasdaq Capital Market or other securities exchange
of the preferred stock covered by such prospectus supplement.
Transfer Agent and Registrar
The transfer agent and
registrar for our capital stock is Computershare Trust Company, N.A. Its address is 250 Royall Street, Canton, MA 02021. Its telephone
number is (201) 680-4503.
13
LEGAL MATTERS
The validity of the securities offered hereby is being passed
upon for us by Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C., New York, New York.
EXPERTS
Our consolidated financial statements appearing in our
Annual
Report on Form 10-K for the year ended December 31, 2019
, have been audited by Moss Adams LLP, an independent registered
public accounting firm, as stated in their report, which is incorporated herein by reference. Such consolidated financial
statements have been so incorporated in reliance upon the report of such firm (which report expresses an unqualified opinion
and includes an explanatory paragraph regarding the Company's going concern uncertainty) given upon their authority as
experts in accounting and  auditing.
WHERE YOU CAN FIND MORE INFORMATION
We are a reporting company and file annual, quarterly and current
reports, proxy statements and other information with the SEC. We have filed with the SEC a registration statement on Form S-1 under
the Securities Act with respect to the offer and sale of our securities under this prospectus. This prospectus does not contain
all of the information set forth in the registration statement and the exhibits to the registration statement. For further information
with respect to us and the securities offered under this prospectus, we refer you to the registration statement and the exhibits
filed as a part of the registration statement. The SEC also maintains an Internet site that contains reports, proxy and information
statements and other information regarding issuers that file electronically with the SEC, including SELLAS Life Sciences Group,
Inc. The SEC's Internet site can be found at www.sec.gov. We maintain a website at www.sellaslife.com. Information found
on, or accessible through, our website is not a part of, and is not incorporated into, this prospectus, and you should not consider
it part of this prospectus.
INCORPORATION OF DOCUMENTS BY REFERENCE
The SEC allows us to incorporate by reference the information
we file with it, which means that we can disclose important information to you by referring you to another document that we have
filed separately with the SEC. You should read the information incorporated by reference because it is an important part of this
prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to
the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information
in this prospectus. We incorporate by reference into this prospectus and the registration statement of which this prospectus is
a part the information or documents listed below that we have filed with the SEC (Commission File No. 001-33958):
·
our definitive proxy statement on Schedule 14A filed with the SEC on April 23, 2020;
·
our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 13, 2020;
·
our Quarterly Report on Form 10-Q for the three months ended March 31, 2020, filed with the SEC on May 14, 2020;
·
our Current Reports on Form 8-K, filed with the SEC on
January 7, 2020
,
January 10, 2020
, and
March 13, 2020
; and
·
the description of our common stock set forth in our registration statement on Form 8-A, filed with the SEC on
February 8, 2008, as amended on February 12, 2008, including any further amendments thereto or reports filed for the purposes of updating this description.
We also incorporate by reference any future filings (other than
current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items
unless such Form 8-K expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the
Exchange Act, including those made after the date of the initial filing of the registration statement of which this prospectus
is a part and prior to effectiveness of such registration statement, until we file a post-effective amendment that indicates the
termination of the offering of the common stock made by this prospectus and will become a part of this prospectus from the date
that such documents are filed with the SEC. Information in such future filings updates and supplements the information provided
in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information
in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent
that statements in the later filed document modify or replace such earlier statements.
We will furnish without charge to each person, including any
beneficial owner, to whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents incorporated
by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated
by reference into such documents. You should direct any requests for documents to SELLAS Life Sciences Group, Inc., Attention:
Corporate Secretary, 15 West 38
th
Street, 10th Floor, New York, New York 10018. Our phone number is (917) 438-4353.
You should rely only on information contained in, or
incorporated by reference into, this prospectus and any prospectus supplement. We have not authorized anyone to provide you
with information different from that contained in this prospectus or incorporated by reference into this prospectus. We are
not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in
which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such
offer or solicitation.
14
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 13.
Other Expenses of Issuance and Distribution.
The following table sets forth the expenses to be incurred in
connection with the offering described in this Registration Statement, other than underwriting discounts and commissions, all which
will be paid by the Registrant. All amounts are estimates except the Securities and Exchange Commission, or SEC, registration fee
and the Financial Industry Regulatory Authority, Inc., filing fee.
Amount
Securities and Exchange Commission registration fee
$
417.73
Accountant's fees and expenses
15,000
Legal fees and expenses
30,000
Miscellaneous
10,000
Total expenses
$
45,417.73
Item 14.
Indemnification of Directors and Officers.
As permitted by Section 102 of the Delaware General Corporation
Law, we have adopted provisions in our amended and restated certificate of incorporation and amended and restated bylaws, each
as amended, which limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as a
director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business
judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable
to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:
·
any breach of the director's duty of loyalty to us or our stockholders;
·
any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
·
any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or
·
any transaction from which the director derived an improper personal benefit.
These limitations of liability do not affect the availability
of equitable remedies such as injunctive relief or rescission. Our amended and restated certificate of incorporation also authorizes
us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law.
As permitted by Section 145 of the Delaware General Corporation
Law, our amended and restated bylaws, as amended, provide that:
·
we may indemnify our directors, officers and employees to the fullest extent permitted by the Delaware General Corporation
Law, subject to limited exceptions;
·
we may advance expenses to our directors, officers and employees in connection with a legal proceeding to the fullest extent
permitted by the Delaware General Corporation Law, subject to limited exceptions; and
·
the rights provided in our bylaws are not exclusive.
Our amended and restated certificate of incorporation and bylaws,
each as amended, which are filed as Exhibits 3.1 and 3.3, provide for the indemnification provisions described above and elsewhere
herein. We have entered into separate indemnification agreements with our directors and officers that may be broader than the specific
indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements generally require
us, among other things, to indemnify our officers and directors against liabilities that may arise by reason of their status or
service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also
generally require us to advance any expenses incurred by the directors or officers as a result of any proceeding against them as
to which they could be indemnified. In addition, we have purchased a policy of directors' and officers' liability insurance
that insures our directors and officers against the cost of defense, settlement or payment of a judgment in some circumstances.
These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of our
officers and directors for liabilities, including reimbursement of expenses incurred, arising under the Securities Act.
We have entered into indemnification agreements with our directors
and executive officers, in addition to the indemnification provided for in our amended and restated certificate of incorporation
and amended and restated bylaws, and intend to enter into indemnification agreements with any new directors and executive officers
in the future.
We have purchased and currently intend to maintain insurance
on behalf of each and every person who is or was a director or officer of our company against any loss arising from any claim asserted
against him or her and incurred by him or her in any such capacity, subject to certain exclusions.
Item 15.
Recent Sales of Unregistered Securities.
Since March 31, 2017, the registrant has issued unregistered
securities to the persons, as described below. None of these transactions involved any underwriters, underwriting discounts or
commissions, except as specified below, or any public offering, and the registrant believes that, except as set forth below, each
transaction was exempt from the registration requirements of the Securities Act of 1933 by virtue of Section 4(2) or Section 3(a)(10)
thereof and/or Regulation D or Regulation S promulgated thereunder. All recipients had adequate access, though their relationships
with the registrant, to information about the registrant.
a)
In July 2017, the registrant entered into a binding settlement term sheet, pursuant to which the registrant agreed to pay a
portion of the settlement agreement ($1,250,000) in unrestricted shares of its common stock, which valuation will be based on the
volume-weighted average closing price for the 20 trading days immediately preceding the day before the transfer of the settlement
stock to the settlement fund pursuant to the terms and conditions of the settlement. Such shares were issued in June 2018.
b)
In February-May 2018, the registrant issued an aggregate of 1,092 shares of its common stock in exchange for the surrender
and cancellation of warrants to acquire 2,433 shares of its common stock, and $1.0 million in convertible promissory notes in exchange
for the surrender and cancellation of warrants to acquire 8,253 shares of its common stock, pursuant to individual agreements with
nine accredited investors; the cancelled warrants were issued to the holders thereof in a February 2017 registered offering. In
April 2018, $0.8 million of outstanding principal and accrued interest of the convertible promissory notes was converted into 2,372
shares of common stock.
c)
In March 2018, the registrant entered into a purchase agreement providing for the sale and issuance of an aggregate of 10,700
shares of its 20% non-voting Series A Convertible Preferred Stock (or Series A) and warrants to acquire an aggregate of 27,672
shares of its common stock to seven accredited investors. The securities were issued in two tranches (in March 2018 and May 2018),
for aggregate gross proceeds of $10.7 million of cash. Cantor Fitzgerald & Co. acted as placement agent and received a fee
equal to 7% of the gross proceeds received from U.S-based investors, as well as reimbursement for its actual, out-of-pocket accountable
expenses (including legal fees and expenses) incurred in connection with the private placement. In May 2018, 2,898 shares of Series
A were converted into 9,994 shares of common stock.
d)
In March 2019, the registrant entered into a Warrant Exercise Agreement which (i) amends the warrants issued in July 2018 to
reduce the exercise price per share of such warrants and (ii) provides for the issuance of new warrants to purchase up to an aggregate
of approximately 76,000 shares of the registrant's common stock (the "New Warrants"). The New Warrants are exercisable
after the six-month anniversary of issuance and terminate on the five-year anniversary following the initial exercise date. The
New Warrants have an exercise price per share of $70.00.
e)
In January 2020, the registrant entered into a securities purchase agreement pursuant to which the registrant agreed to issue
to investors who participated in a registered direct offering warrants (the "Warrants") exercisable for an aggregate
of 818,900 shares of common stock at an exercise price of $3.93 per share. Each Warrant was immediately exercisable and will expire
five and one-half years from the issuance date.
Item 16.
Exhibits and Financial Statement Schedules.
See Exhibit Index following the
signature page to this Registration Statement.
Item 17.
Undertakings.
The undersigned registrant hereby undertakes:
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most
recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information
set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered
(if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or
high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant
to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate
offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement;
(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement;
provided, however, that paragraphs (a)(1)(i), (ii), and (iii)
of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained
in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities
Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement.
(2)
That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
at the termination of the offering.
(4)
That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution
of the securities:
The undersigned registrant undertakes that in a primary offering
of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used
to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities
to such purchaser:
(i)
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant
to Rule 424;
(ii)
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred
to by the undersigned registrant;
(iii)
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned
registrant or its securities provided by or on behalf of the undersigned registrant; and
(iv)
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
The undersigned registrant hereby undertakes that, for purposes
of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant to section
13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's
annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration
statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial
bona fide
offering thereof.
Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers, and controlling persons of the registrant pursuant to the foregoing provisions,
or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
The undersigned registrant hereby undertakes that:
(1)
For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed
as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant
pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement
as of the time it was declared effective.
(2)
For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of these
securities at that time shall be deemed to be the initial bona fide offering.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933,
the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized
in the city of New York, New York, on this May 29, 2020.
SELLAS LIFE SCIENCES GROUP, INC.
By:
/s/ Angelos M. Stergiou
Name:
Angelos M. Stergiou, M.D., Sc.D., h.c.
Title:
President and Chief Executive Officer
POWER OF ATTORNEY
We, the undersigned officers and directors
of SELLAS Life Sciences Group, Inc., hereby severally constitute and appoint Angelos M. Stergiou and John Burns, and each of them
singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in
the capacities indicated below, the registration statement on Form S-1 filed herewith, and any and all pre-effective and post-effective
amendments to said registration statement, and any registration statement filed pursuant to Rule 462(b) under the Securities Act
of 1933, as amended, in connection with the registration under the Securities Act of 1933, as amended, of equity securities of
the Company, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith,
with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and
perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes
as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their
substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.
Pursuant to the requirements of the Securities
Act of 1933, this Registration Statement on Form S-1 has been signed below by the following persons in the capacities and on the
dates indicated.
Signature
Title
Date
/s/ Angelos M. Stergiou
President, Chief Executive Officer and Director
(Principal Executive and Financial Officer)
May 29, 2020
Angelos M. Stergiou, M.D., Sc.D., h.c.
/s/ John Burns
Vice President, Finance and Corporate Controller
(Interim Principal Accounting Officer)
May 29, 2020
John Burns, C.P.A.
/s/ Jane Wasman
Chair of the Board of Directors
May 29, 2020
Jane Wasman
/s/ David A. Scheinberg
Director
May 29, 2020
David A. Scheinberg, M.D., Ph.D.
/s/ Robert L. Van Nostrand
Director
May 29, 2020
Robert L. Van Nostrand
/s/ John Varian
Director
May 29, 2020
John Varian
EXHIBIT INDEX
The exhibits listed
below are filed as part of or incorporated by reference into this Registration Statement on Form S-1.
Exhibit
Number
Description
Form
Exhibit
Filing Date
2.1^
Agreement and Plan of Merger, dated as of August 7, 2017, by and among the Registrant, Galena Bermuda Merger Sub, Ltd., Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc. and SELLAS Life Sciences Group Ltd, as amended (included as Annex A to the proxy statement/prospectus/consent solicitation statement)
8-K
2.1
August 8, 2017
3.1
Composite Amended and Restated Certificate of Incorporation of the Registrant (formerly, Galena Biopharma, Inc.), amended as of December 27, 2017
10-K
3.1
April 13, 2018
3.2
Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock
8-K
3.1
March 12, 2018
3.3
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant
8-K
3.1
November 6, 2019
3.4
Amended and Restated By-Laws of the Registrant
8-K
3.3
January 5, 2018
4.1**
Form of Common Stock Certificate
10-K
4.1
April 13, 2018
4.2
Form of Contingent Value Rights Agreement among the Registrant (formerly RXi Pharmaceuticals Corporation), Computershare Trust Company, N.A., Computershare Inc., and Robert E Kennedy, dated April 13, 2011
8-K
10.1
April 14, 2011
4.3
First Amendment to Contingent Value Rights Agreement among the Registrant (formerly RXi Pharmaceuticals Corporation), Computershare Trust Company, N.A., Computershare Inc., and Robert E Kennedy, dated February 15, 2012
10-K
10.2
March 28, 2012
4.4
Registration Rights Agreement dated May 10, 2016 between the Registrant and Purchasers
10-Q
10.3
May 10, 2016
4.5
Series A Common Stock Purchase Warrant assigned to JGB (Cayman) Newton Ltd. dated May 10, 2016
10-Q
4.2
May 10, 2016
4.6
Series B Common Stock Purchase Warrant assigned to JGB (Cayman) Newton Ltd. dated May 10, 2016
10-Q
4.3
May 10, 2016
4.7
Subsidiary Guarantee dated May 10, 2016 between the Registrant and JGB Collateral LLC
10-Q
10.2
May 10, 2016
4.8
Security Agreement dated May 10, 2016 between the Registrant and JGB Collateral LLC
10-Q
10.4
May 10, 2016
4.9
Amended and Restated 9% Original Issue Discount Senior Secured Debenture Due November 10, 2018, issued to JGB (Cayman) Newton Ltd. as of August 22, 2016
8-K
4.1
August 23, 2016
4.10
Amendment Agreement, dated as of July 10, 2017, by and between JGB Cayman (Newton) Ltd. and the Registrant with respect to the 9% Original Issue Discount Senior Secured Convertible Debenture in the Original Issue Amount of $25,350,000 Issued and Sold to JGB Cayman (Newton) Ltd. by the Registrant
8-K
4.1
July 11, 2017
4.11
Consent, dated as of August 7, 2017, made by JGB (Cayman) Newton Ltd., in favor of the Registrant
8-K
10.3
August 8, 2017
4.12
Form
    of warrants granted on May 8, 2013 under the Loan and Security Agreement
10-Q
10.7
May
    9, 2013
4.13
Form of Warrant Agreement by and among the Registrant, Computershare Inc. and Computershare Trust Company, N.A.
8-K
4.1
September 18, 2013
4.14
Warrant Agreement, dated as of March 18, 2015, by and among the Registrant, Computershare, Inc. and Computershare Trust Company, N.A.
10-Q
4.1
August 6, 2015
4.15
Form of Warrant Agreement by and among the Registrant, Computershare Inc. and Computershare Trust Company, N.A.
8-K
4.1
January 7, 2016
4.16
Form of Warrant, issued by the Registrant to the Investors on July 13, 2016
8-K
4.1
July 8, 2016
4.17
Form of Warrant Agreement, including the Form of Warrant, issued by the Registrant to the Investors on February 13, 2017
8-K
4.1
February 10, 2017
4.23
Warrant issued to EQC Private Markets SAC Fund Ltd – EQC Biotech Sely I Fund
8-K
10.5
January 5, 2018
4.18
Warrant Exchange Agreement by and between the Registrant and CVI Investments, Inc., dated February 6, 2018
10-K
10.73
April 13, 2018
4.19
Promissory Note by and between the Registrant and CVI Investments, Inc., dated February 6, 2018
10-K
10.74
April 13, 2018
4.20
Warrant Exchange Agreement by and between the Registrant and Anson Investments Master Fund LP, dated February 7, 2018
10-K
10.75
April 13, 2018
4.21
Warrant Exchange Agreement by and between the Registrant, Sabby Healthcare Master Fund Ltd and Sabby Volatility Warrant Master Fund Ltd, dated February 8, 2018
10-K
10.76
April 13, 2018
4.22
Warrant Exchange Agreement by and between the Registrant and Hudson Bay Master Fund Agreement, dated February 9, 2018
10-K
10.77
April 13, 2018
4.23
Promissory Note by and between the Registrant and Hudson Bay Master Fund Agreement, dated February 9, 2018
10-K
10.78
April 13, 2018
4.24
Warrant Exchange Agreement by and between the Registrant and Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, dated February 13, 2018
10-K
10.79
April 13, 2018
4.25
Promissory Note by and between the Registrant and Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, dated February 13, 2018
10-K
10.80
April 13, 2018
4.26
Warrant Exchange Agreement by and between the Registrant and Lincoln Park Capital LLC, dated February 14, 2018
10-K
10.81
April 13, 2018
4.27
Warrant Exchange Agreement by and between the Registrant and Empery Asset Master, Ltd., dated February 21, 2018
10-K
10.82
April 13, 2018
4.28
Warrant Exchange Agreement by and between the Registrant and Empery Tax Efficient, LP, dated February 21, 2018
10-K
10.83
April 13, 2018
4.29
Warrant Exchange Agreement by and between the Registrant and Empery Tax Efficient II, LP, dated February 21, 2018
10-K
10.84
April 13, 2018
4.30
Promissory Note by and between the Registrant and Empery Asset Master, Ltd., dated February 21, 2018
10-K
10.85
April 13, 2018
4.31
Promissory Note by and between the Registrant and Empery Tax Efficient, LP, dated February 21, 2018
10-K
10.86
April 13, 2018
4.32
Promissory Note by and between the Registrant and Empery Tax Efficient II, LP, dated February 21, 2018
10-K
10.87
April 13, 2018
4.33
Warrant Agreement including form of accompanying Common Warrant as Exhibit B thereto, dated as of July 16, 2018, among the Registrant, Computershare, Inc., and Computershare Trust Company N.A.
8-K
10.1
July 18, 2018
4.34
Amendment to Warrant Agreement including form of accompanying Common Warrant as Exhibit B thereto, dated as of July 16, 2018, among the Registrant, Computershare, Inc., and Computershare Trust Company N.A.
8-K
10.2
July 9, 2019
4.35
Form of Pre-funded Warrant in connection with July 2018 public offering
8-K
10.2
July 18, 2018
4.36
Form of Warrant issued in exchange of Series A Preferred Stock in connection with July 2018 public offering
8-K
10.3
July 18, 2018
4.37
Warrant Exchange Agreement by and between the Registrant and Intracoastal Capital LLC dated May 25, 2018 (including as Exhibit A thereto, that certain Convertible Promissory Note by and between the Registrant and Intracoastal Capital LLC dated May 25, 2018)
8-K
10.1
June 1, 2018
4.38
Form of New Warrant issued in connection with Warrant Exercise Agreement dated March 6, 2019
8-K
4.1
March 6, 2019
4.39
Warrant Agreement, including form of accompanying Common Warrant as Exhibit B thereto, dated as of June 18, 2019, among the Registrant, Computershare Inc., and Computershare Trust Company N.A.
8-K
10.1
June 18, 2019
4.40
Form of Pre-Funded Warrant in connection with June 2019 public offering
8-K
10.2
June 18, 2019
5.1*
Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
9.1
Securities Purchase Agreement dated March 7, 2018 by and between the Registrant and certain investors
8-K
10.1
March 12, 2018
10.1**
The Registrant's 2016 Incentive Plan effective as of July 14, 2016
8-K
10.3
August 22, 2016
10.2**
Form Incentive Stock Option granted under the Registrant's 2016 Incentive Plan
10-Q
10.1
August 8, 2015
10.3**
Form Nonstatutory Stock Option granted under the Registrant's 2016 Incentive Plan
10-Q
10.2
August 8, 2015
10.4**
SELLAS Life Sciences Group, Ltd Stock Incentive Plan #1
S-4/A
10.61
October 30, 2017
10.5**
Form of Restricted Stock Unit Grant and Agreement under SELLAS Life Sciences Group Ltd Stock Incentive Plan #1
S-4/A
10.63
October 30, 2017
10.6**
2017 Equity Incentive Plan of the Registrant
8-K
10.10
January 5, 2018
10.7**
2017 Employee Stock Purchase Plan of the Registrant
8-K
10.11
January 5, 2018
10.8**
Form of Stock Option Grant Notice and Option Agreement under the 2017 Equity Incentive Plan.
8-K
10.2
March 19, 2018
10.9**
Form of Restricted Stock Unit Grant and Agreement under the 2017 Equity Incentive Plan.
10-K
10.9
April 13, 2018
10.10**
Employment Agreement by and between SELLAS Life Sciences Group AG and Angelos Stergiou, effective September 1, 2016
S-4/A
10.53
October 30, 2017
10.11**
Employment Agreement by and between SELLAS Life Sciences Group AG and Gregory Torre, effective September 1, 2016
S-4/A
10.54
October 30, 2017
10.12**
Employment Agreement by and between SELLAS Life Sciences Group AG and Nicholas Sarlis, effective September 19, 2016
S-4/A
10.55
October 30, 2017
10.13**
Employment Agreement by and between SELLAS Life Sciences Group Ltd and Aleksey Krylov, dated October 24, 2017
S-4/A
10.56
October 30, 2017
10.14**
Retention Agreement Letter by and between SELLAS Life Sciences Group Ltd and Gregory Torre, dated July 31, 2017
S-4/A
10.57
October 30, 2017
10.15**
Retention Agreement Letter by and between SELLAS Life Sciences Group Ltd and Nicholas Sarlis, dated August 2, 2017
S-4/A
10.58
October 30, 2017
10.16**
Letter Employment Agreement by and between SELLAS Life Sciences Group, Inc. and Barbara Wood, dated March 14, 2018
8-K
10.1
March 19, 2018
10.17+
Patent and Technology License Agreement, dated September 11, 2006, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)
10-Q
10.1
August 15, 2011
10.18
Amendment No. 1 to Patent and Technology License Agreement, dated December 21, 2007, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)
10-Q
10.2
August 15, 2011
10.19
Amendment No. 2 to Patent and Technology License Agreement, dated September 3, 2008, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)
10-Q
10.3
August 15, 2011
10.20
Amendment No. 3 to Patent and Technology License Agreement, dated July 8, 2009, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)
10-Q
10.4
August 15, 2011
10.21+
Amendment No. 4 to Patent and Technology License Agreement, dated February 11, 2010, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)
10-Q
10.5
August 15, 2011
10.22+
Amendment No. 5 to Patent and Technology License Agreement, dated January 10, 2011, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)
10-Q
10.6
August 15, 2011
10.23
Scientific Advisory Agreement between the Registrant (formerly Galena Biopharma, Inc.) and George E. Peoples, Ph.D., dated April 13, 2011
10-Q
10.10
August 15, 2011
10.24+
Exclusive License Agreement, dated as of July 11, 2011, by and among The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., the Registrant (formerly Galena Biopharma, Inc.) and its wholly owned subsidiary, Apthera, Inc.
10-Q
10.12
August 15, 2011
10.25+
Exclusive License Agreement, dated as of September 16, 2011, by and among The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Board of Regents of the University of Texas System, The University of Texas M. D. Anderson Cancer Center and the Registrant (formerly Galena Biopharma, Inc.)
8-K
10.1
September 21, 2011
10.26+
License Agreement, effective as of April 30, 2009, between Kwangdong Pharmaceutical Co., Ltd. and Apthera, Inc.
10-K
10.45
March 28, 2012
10.27
Amendment No. 1 to License Agreement, dated as of January 13, 2012, by and among Apthera, Inc., Kwangdong Pharmaceutical Co., Ltd., and the Registrant
10-K
10.46
March 28, 2012
10.28+
License and Supply Agreement, effective December 3, 2012, by and between the Registrant and ABIC Marketing Limited, a subsidiary of Teva Pharmaceuticals
10-K
10.43
March 12, 2013
10.29+
License and Development Agreement, dated January 13, 2014, between the Registrant and Dr. Reddy's Laboratories, Ltd.
10-K
10.36
March 17, 2014
10.30+
Exclusive License Agreement, dated as of December 20, 2013, between Mills Pharmaceuticals, LLC and BioVascular, Inc.
10-K
10.37
March 17, 2014
10.31
Amendment of the Exclusive License Agreement by and between Mills Pharmaceuticals, LLC and BioVascular, Inc.
8-K
10.1
September 11, 2017
10.32
License Agreement by and between SELLAS Life Sciences, Inc. and Madison Avenue Suites LLC, dated March 20, 2017
S-4/A
10.64
October 30, 2017
10.33+
Amended and Restated Exclusive License Agreement by and between SELLAS Life Sciences Group Ltd and Memorial Sloan Kettering Cancer Center, effective October 11, 2017
S-4/A
10.65
October 30, 2017
10.34
Form of Indemnity Agreement between the Registrant and each of its directors and executive officers
8-K
10.8
January 5, 2018
10.35
License Agreement made as of May 19, 2018 by and between the Registrant and 38th Street Suites LLC
8-K
10.1
May 24, 2018
10.36
Surrender Agreement made as of May 19, 2018 by and between the Registrant and Madison Avenue Suites LLC
8-K
10.2
May 24, 2018
10.37
Settlement Agreement between SELLAS Life Sciences Group, Inc. and individual named defendants, on the one hand, and JGB (Cayman) Newton, Ltd., JGB Collateral LLC, JGB Capital Offshore Ltd., JGB Partners L.P., and JGB Capital L.P., on the other hand, dated as of November 5, 2018
8-K
10.1
November 9, 2018
10.38
Securities Purchase Agreement dated May 10, 2016 between the Registrant and Purchasers
10-Q
10.1
May 10, 2016
10.39
Amendment Agreement between the Registrant and JGB (Cayman) Newton Ltd. dated August 22, 2016.
8-K
10-1
August 23, 2016
10.40
Waiver dated December 14, 2016 to the Securities Purchase Agreement, dated as of May 10, 2016, by and between Registrant and JGB (Cayman) Newton Ltd.
8-K
10.3
February 7, 2017
10.41
Waiver dated April 1, 2017 to the Securities Purchase Agreement dated as of May 10, 2016 by and between the Registrant and JGB (Cayman) Newton Ltd.
8-K
10.1
April 3, 2017
10.42
Form of Voting Agreement by and between the Registrant and its named executive officers, Board of Directors and certain stockholders
8-K
10.2
March 12, 2018
10.43
Form of Warrant issued pursuant to that certain Securities Purchase Agreement dated March 7, 2018 by and between the Registrant and certain investors
8-K
4.1
March 12, 2018
10.44
Form of Warrant Exercise Agreement dated March 6, 2019
8-K
10.1
March 6, 2019
10.45
Amendment Agreement dated May 1, 2017 between the Registrant and JGB (Cayman) Newton Ltd.
8-K
10.1
May 2, 2017
10.46
Equity Distribution Agreement dated October 29, 2019, between the Registrant and Maxim Group LLC
8-K
10.1
October 31, 2019
10.47
Form of Investor Agreement
8-K
10.1
July 9, 2019
10.48
Form of Stock Option Grant Notice and Option Agreement under the 2019 Equity Incentive Plan.
10-K
10.48
March 13, 2020
10.49
Form of Restricted Stock Unit Grant and Agreement under the 2019 Equity Incentive Plan.
10-K
10.49
March 13, 2020
14.1
Code of Business Conduct and Ethics
8-K
14.1
January 5, 2018
21.1
Subsidiaries of the Registrant
10-K
21.1
April 13, 2018
23.1*
Consent of Moss Adams LLP, Independent Registered Public Accounting Firm
23.2*
Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1).
24.1
Powers of Attorney (included on signature page hereto)
*
Filed herewith.
**
Indicates management contract or compensatory plans or
arrangements.
^
The schedules and exhibits to this exhibit have been
omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC
upon request.
+
Confidential treatment has been granted with respect
to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.